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The methylation of arginine residues is a prevalent post-translational 
modification, found on both nuclear and cytoplasmic proteins, catalyzed by 
the protein arginine N-methyltransferase (PRMT) family of enzymes. To date 
there have been only a few publications describing small-molecule chemical 
modulators of the PRMTs. In this thesis are report the synthesis of a number of 
compounds structurally related to arginine methyltransferase inhibitor 1 
(AMI-1). The structural alterations that we made included: 1) the substitution 
of the sulfonic groups with the bioisosteric carboxylic groups; 2) the 
replacement of the ureidic function with a bisamidic and mixed urea-amidic 
moiety; 3) the introduction of a N-containing basic moiety; 4) the positional 
isomerization of the amino- hydroxynaphthoic moiety; and 5) bioisosteric 
substitution of naphthol with indole. The biological activity of these 
compounds has been assessed against a panel of arginine methyltransferases 
(fungal RmtA, hPRMT1, hCARM1, hPRMT3, hPRMT6) and lysine 
methyltransferase (SET7/9 and G9a) using histone and nonhistone proteins as 
substrates. Molecular modeling studies for a deep binding-mode analysis of 
test compounds were also performed. The bis-carboxylic acid derivatives 1b 
and 7b emerged as the most effective PRMT inhibitors, both in vitro and in 
vivo, being comparable or even better than the reference compound (AMI-1) 
and practically inactive against the lysine methyltransferase SET7/9. We also 
identified 33a as the first powerful and selective activator of CARM-1. 
Moreover an enantioselective α-amination of aryl oxindoles catalyzed by a 
dimeric quinidine has been developed. This procedure is general, broad in 
substrate scope, and affords the desired products in good yields with good to 





































                                                                                         Chapter 1:Introduction 
1.1 Epigenetics 
There are several existing definitions of epigenetics, the most 
comprehensive and up to date is: “The structural adaptation of chromosomal 
regions so as to register, signal or perpetuate altered activity states”1. This 
definition is inclusive of chromosomal marks, because transient modifications 
associated with both DNA repair or cell-cycle phases and stable changes 
maintained across multiple cell generations qualify. It focuses on 
chromosomes and genes, implicitly excluding potential three-dimensional 
architectural templating of membrane systems and prions, except when these 
impinge on chromosome function. Also included is the exciting possibility that 
epigenetic processes are buffers of genetic variation, pending an epigenetic (or 
mutational) change of state that leads an identical combination of genes to 
produce a different developmental outcome. An implicit feature of this 
proposed definition is that it portrays epigenetic marks as responsive, not 
proactive. In other words, epigenetic systems of this kind would not, under 
normal circumstances, initiate a change of state at a particular locus but would 
register a change already imposed by other events. 
 
1.2 Histone modifications  
The nucleosome is the fundamental unit of chromatin structure in all 
eukaryotes. It comprises a core of eight histones (two H2A, H2B, H3 and H4 
histones) around which 147 base pairs of DNA are wrapped in 1.75 
superhelical turns2. Given the intimate association between histones and DNA, 
it is not surprising that histones influence almost every aspect of DNA 
function. In some cases they are influential just by their presence — for 
example by hiding or revealing transcription factor binding sites or influencing 
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depend on chemical modification of specific histone amino acids. The amino-
terminal tails of all eight core histones protrude through the DNA and are 
exposed on the nucleosome surface, where they are subject to an enormous 
range of enzyme-catalyzed modifications of specific amino-acid side chains3, 
include acetylation of lysines, methylation of lysines and arginines, and 
phosphorylation of serines and threonines. Histone modifications are 
functionally linked to a variety of processes that are continuously occurring 
within the cell — for example, transcriptionally active promoters show an 
overall increase in acetylation of core histones and a more selective increase in 
methylation at particular lysines and arginines3b. Patterns of histone 
modification associated with ongoing transcription can change rapidly and 
cyclically in response to external stimulation. In this context, histone 
modifications can be considered the endpoints, on chromatin, of cellular 
signaling pathways and a mechanism through which the genome can respond 
to environmental stimuli. To allow such responses, it is likely that the 
modifications themselves are rapidly turning over4. Histones can also exert 
longer-term effects on genomic function, largely by defining and maintaining 
chromatin structures throughout the cell cycle, or from one cell generation to 
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proline isomerization. Most modifications have 
been found to be dynamic, and enzymes that remove the modification have 
be
Figure 1.1 Histone modifications can generate both short-term and long-term outcomes. 
Histone tail modifications are put in place by modifying and demodifying enzymes, whose 
activities can be modulated by environmental and intrinsic signals. Modifications may 
function in both short-term, ongoing processes (such as transcription, DNA replication and 
repair) and in more long-term functions (as determinants of chromatin conformation, for 
example, heterochromatin formation, or as heritable markers that both predict and are 
necessary for, future changes in transcription). Short-term modifications are transient and 
show rapidly fluctuating levels. Long-term, heritable modifications need not necessarily be 
static: in theory they could still show enzyme-catalyzed turnover, but the steady-state level 
must be relatively consistent. 
 
The identification of the enzymes that directly modify histones has been the 
focus of intense activity over the last 10 years. Enzymes have been identified 
for acetylation, phosphorylation ubiquitination, sumoylation, ADP-
ribosylation, deimination, and 







                                                                                         Chapter 1:Introduction 
There are two characterized mechanisms for the function of modifications. 
The first is the disruption of contacts between nucleosomes in order to 
‘‘unravel’’ chromatin and the second is the recruitment of nonhistone proteins. 
The second function is the m
f the 
lysine. 
The abundance of modifications on the histone tail makes ‘‘crosstalk’’ 
between modifications very likely (Figure 1.2)5. Mechanistically such 
communication between modifications may occur at several different levels. 
Firstly, many different types of modification occur on lysine residues. This 
will undoubtedly result in some form of antagonism since distinct types of 
modifications on lysines are mutually exclusive. Secondly, the binding of a 
protein could be disrupted by an adjacent modification. The best example of 
this being that of phosphorylation of H3S10 affecting the binding of HP1 to 
compromised by modification of its substrate recognition site; for example, 
isomerization of H3P38 affects methylation of H3K36 by Set27. Fourthly, an 
ost characterized to date. Thus, depending on the 
composition of modifications on a given histone, a set of proteins are 
encouraged to bind or are occluded from chromatin. These proteins carry with 
them enzymatic activities (e.g., remodeling ATPases) that further modify 
chromatin. The need to recruit an ordered series of enzymatic activities comes 
from the fact that the processes regulated by modifications (transcription, 
replication, repair) have several steps. Each one of these steps may require a 
distinct type of chromatin-remodeling activity and a different set of 
modifications to recruit them. 
Modifications may affect higher-order chromatin structure by affecting the 
contact between different histones in adjacent nucleosomes or the interaction 
of histones with DNA. Of all the known modifications, acetylation has the 
most potential to unfold chromatin since it neutralizes the basic charge o
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en  in the context of a 
second modification; the example here is the GCN5 acetyltransferase, which 
ma
gure 1.2 Crosstalk between Histone The positive influence of one modification over 
ano  is shown by an arrow and the negative effect by a dish-line. 
1.3 Histone arginine methyltransferases (PRMTs) 
zyme could recognize its substrate more effectively





The methylation of proteins and the enzymes that carry out these reactions 
increased the dimensions of the regulation of gene transcription by marking 
genes to be or not to be transcribed9. Protein methylation can occur on amino 
acids such as lysine, arginine, histidine, or proline, and on carboxy groups10. 
Arginine methylation of mainly nuclear proteins is an important 
posttranslational modification process involved in structural remodeling of 
chromatin, signal transduction, cellular proliferation, nucleocytoplasmatic 
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1.3.1. Biochemical reaction of PRMTs 
The PRMT enzymes remove one residue, the methyl group, from the donor 
molecule S-adenosyl- L-methionine (AdoMet) to generate the product S-
adenosyl- L-homocystein (AdoHcy), and hereby transferring the residue to an 
acceptor molecule which is the terminal nitrogen atom of the guanidinium side 
chain of an individual arginin 12e residue in the target protein (Figure 1.3) . As 
there are three nitrogens in the guanidine group, putatively all of them could 
be
third methylated arginine is 
generated by monomethylation of the internal δ-guanidino nitrogen atom of 
arginine (δ-N-methyl-L-arginine) and has so far been documented only for 
yeast proteins14. According to their methylation status, the PRMT enzymes 
were classified into different group types. While the type-I PRMT enzymes 
catalyze the formation of MMA and aDMA, the type-II PRMT enzymes form 
MMA and sDMA. The enzymes PRMT1, PRMT3, PRMT4, PRMT6, or 
PRMT8 belonging to the type-I and PRMT5, PRMT7, or PRMT9 to the type-
II enzymes13b, 15. Finally, type-III PRMT enzymes catalyze methylation at the 
δ-guanidino group in yeast14 . 
Only very recently have different enzymes been identified which counteract 
the methylation process by catalyzing a demethylation step and so remove 
me ns (e.g., LSD1, JMJD6). It should be 
pointed out that JMJD6, a Jumonjidomain-containing protein, is the only 
arginine specific demethylase so far identified16. 
 
 methylated; the two ω-guanidino nitrogen atoms and the internal δ-
guanidino nitrogen atom13. Indeed, mono- and dimethylation reactions of 
arginine are found to occur in mammalians: ω-NG-monomethylarginine 
(MMA), symmetric ω-NG,N’G -dimethylarginine (sDMA), or asymmetric ω-
NG,NG dimethylarginine (aDMA) (Fig. 3). The 





















Figure 1.3 Methylation of the arginine side chain by PRMTs. Depicted is the amino acid 
arginine in target proteins. Type-I and type-II enzymes catalyze the formation of MMA by 
transfer of a methyl group to the x-guanidino group. In addition, transfer of an additional 
methyl group results in aDMA (type-I enzymes), or sDMA (type-II enzymes). Type-III 
enzymes transfer the methyl group to the internal d-nitrogen. 
 
1.3.2. PRMTs in mammalian, characterization and biological role 
1.3.2.1 PRMT1 
PRMT1 was the first protein arginine N-methyltransferase in mammalian 
cells to be cloned and discovered independently from different groups as a 
protein interacting with the mammalian intermediate early TIS21 protein and 
the leukemia-associated BTG1 protein, or with the intracellular domain of the 
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mammalian cells and tissues is expressed in every cell type investigated18. 
Two important processes mediated by PRMT1 are the methylation of histone 
H4 to regulate gene transcription and of the elongation factor SPT5 which 
regulates its interaction with RNA polymeraseII19. Furthermore, PRMT1 
methylates proteins involved in RNA processing such as poly(A)-binding 
proteins and proteins in DNA repair and checkpoint control20. Besides 
ribosomal and RNA-binding proteins, a kinase adaptor protein (SAM68) is 
methylated by PRMT1 indicating a role in cell cycle regulation21. 
1.3.2.2 PRMT3 
PRMT3 belongs to the type-I enzyme and is expressed widely in human 
tis
f
sues with subcellular localization in the cytoplasm13a. An important feature 
of PRMT3 is the ZnF domain in the amino-terminal part of the protein Using 
deletion studies o  this motif, it was concluded that this domain confers 
substrate specificity and appears to be required for the enzyme to bind and 
methylate target proteins associated with RNA22. PRMT3 was able to transfer 
methyl groups to ribosomal and RNAbinding proteins. Interestingly, the 
interaction of a tumor suppressor gene important in lung carcinomas (DAL-
1/4.1B) with PRMT3 inhibited its ability to methylate cellular substrates and 
modulated its enzymatic activity negatively. This suggested an important 
mechanism through which the suppressor gene was able to affect tumor cell 
growth23. 
1.3.2.3 CARM1 (PRMT4) 
PRMT4 belongs to the type-I class of PRMT enzymes and its gene is 
expressed in all tissues investigated with an increased expression in heart, 
kidney, and testis24. The PRMT4 protein is able to bind directly to the p160 
family of coactivators and in doing so amplifying the nuclear receptor 
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synergistically enhance the nuclear receptor function and influence gene 
activation of ER or AR regulated genes25. In addition, the coactivator function 
of PRMT4 relies on its ability to transfer the methyl group to the amino-
terminal tail of histone H3 after recruitment to the promoter by nuclear 
receptors and p160 coactivators. This is believed to link the process of 
methylation directly with transcriptional function24. A positive regulation of 
cell cycle gene like cyclin E and an involvement in estrogen stimulated breast 
tumors was described for PRMT4. The methylation of SRC3 by PRMT4 
decreased the ER-mediated transactivation suggesting that PRMT4 not only 
activ ut also terminates hormone signaling by disassembly 
of the coactivator complex26. The nuclear localization of PRMT4 propose an 
inv
 activation by the tumor suppressor p5330. 
ates transcription b
olvement in muscle differentiation where PRMT4 plays a fundamental role 
during skeletal myogenesis by activating specifically myogenic genes27. 
Embryos with a targeted disruption of PRMT4 were small in size, died 
perinatally and had a defect during T-cell development. In these animals, 
estrogen-responsive gene expression was aberrant indicating genetic evidence 
for an important role of PRMT4 in hormone mediated transcriptional 
regulation28. Recently, it was shown that PRMT4 is involved in lipid 
metabolism by promoting adipocyte differentiation, suggesting an important 
role in adipose tissue biology29. Finally, it was described that PRMT4 was able 
to cooperate with PRMT1 and be involved in STAT5- and NF-jB-dependent 
gene expression or in transcriptional
1.3.2.4 PRMT5 
PRMT5 was isolated in a two-hybrid search for proteins interacting with 
the Janus tyrosine kinase (Jak2), implying a role in cytokine-activated 
transduction pathways. In human tissues, PRMT5 is widely expressed with 
some higher level in heart, muscle, and testis31. PRMT5 plays a significant role 
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PRMT5 are important in the regulation of genes such as IL-2 and cyclin E1. In 
addition, PRMT5 was able to transfer methyl residues to the tumor suppressor 
p53 and help to discriminate between the cell cycle response and the apoptotic 
response. Furthermore, as arginine methylation has the potential to alter the 
effects of p53 activation, it may therefore provide a suitable drug target for the 
ma 32. 





nipulation of the p53 pathway
1.3.2.5 PRMT6 
PRMT6 belongs to the type-I enzyme of PRMTs catalyzing the formation 
of aDMA (Figure 3). Interestingly, the methylation of selected proteins of the 
human immunodeficiency virus type-1 (HIV-1) by PRMT6 down-regulated 
gene expression by acting as a restriction factor for viral replication 
representing a form of innate cellular immunity33. In addition, PRMT6 
methylated proteins from the high mobility group A (HMGA1a) family of 
architectural nuclear factors which were important in chromatin dynamics, 
placing PRMT6 in the context of chromatin structure organization. Recently, 
PRMT6 methylation of arginine in
le in post-translational modification. 
1.3.2.6 PRMT8 
Expression analysis using Northern analysis revealed a unique tissue-
specific expression as PRMT8 transcripts were largely found in human brain. 
Indeed, by using PRMT8 fusion or mutation constructs, it could be shown that 
the cellular localization of PRMT8 is not the nucleus or the cytoplasm but its 
association with the plasma membrane using the unique Myr motif in 
. In addition, it was shown that the interaction between the 
thyltransferase PRMT8 and its potential substrate protein is maintained, 
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has, besides the methyltransferase activity, another additional functional 
activity on the plasma membrane. 
1.3.2.7 Less known PRMTs: 2,7,9,10,11 
PRMT2 transcripts were detected in most human tissues with an increased 
expression in heart, prostate, ovary, and the neuronal system. Analysis using 
two-hybrid screening approaches identified PRMT2 as interacting with 
different nuclear hormone receptors such as the ERa and the androgen receptor 
(AR). The amplification of ER signaling by PRMT2 strongly depends on the 
cellular background and differs between neuroblastoma and prostate cells. 
as histones, 
myelin basic protein, fibrillarin, and spliceosomal proteins. PRMT7 is 
involved in cancer treatm
d by 
motif search using part of the sequence of the conserved methyl donor binding 
dom  
It was shown that the PRMT7 protein is localized in both cellular 
compartments: the nucleus and the cytosol of mammalian cells. PRMT7 was 
initially characterized in hamster cells as a protein that modulates drug 
sensitivity to DNA-damaging agents. PRMT7 is unusual among the other 
family members in that two PRMT core domains are present. For the 
functionality of the enzyme, both domains are required as each separate 
domain was unable to function alone. Beside PRMT5, PRMT7 was 
characterized as a type-II methyltransferase that was able to synthesize sDMA 
residues in proteins and was able to methylate proteins such 
ent as inhibitor of the enzyme activity sensitizing 
cancer cells to chemotherapeutics. 
PRMT9, also known as F-box only protein 11 (FBXO11), was identifie
ain of PRMTs. Recently, an association between polymorphism in the
PRMT9 gene and inflammation of the middle ear was shown, indicating the 
importance of methylation in disease. Interestingly, besides regulating 
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for posttranslational modification of the tumor suppressor gene p53 by 
inhibiting the transcriptional activity without affecting its stability. As PRMT9 
is a Nedd8 ligase for p53, a direct relationship between neddylation of the 
ity is unknown. 
9, it is predicted that 
PRMT11 also has a methyltransferase activity and may belong to the type-II 
of PRMT enzymes, but no biochemical data and functional information are 
nown at this time35. 
1.4 Histone methyltransferases inhibitors 
ights into the mechanism of methyl transfer, the 
search for modulators of histone methyltransferases is still in its infancy, in 
fact there are only few PRMTs inhibitors (PRMTi) and no one in clinical trials 
(Scheme 1.1). The development of PRMTi is not only hampered by the lack of 
crystallographic structural information for enzyme–inhibitor complexes, and 
only few PRMTs crystal structure are known to date36.  
 
 
suppressor protein and the methyltransferase activ
PRMT10 was predicted by its homology to PRMT7. One human transcript 
encoding a protein with 845 amino acids is described. No biochemical activity 
or substrates have been determined but the resemblance to PRMT7 suggested 
that PRMT10 may also belong to the type-II arginine methyltransferases. 
PRMT11 was found by homology search using the sequence of PRMT9. 
GenBank analysis shows a nitrous oxidase accessory protein (NosD) 
conserved C-terminal motif that may be important for inorganic ion transport 
and metabolism. Because of the similarity with PRMT
k
Despite extensive research aimed at better understand the role of PRMTs in 
physiological and pathological pathways, elucidating the structure of these 
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1.4.1 PRMTi obtained by means of high-throughput and virtual screening 
The first inhibitors of protein arginine methyltransferases were discovered
in 2004 by using the yeast arginine methyltransferase enzyme Hmt1p and the














 Scheme 1.1 Inhibitors of PRMTs trough random and virtual screening.  
 
The screen resulted in the discovery of nine potent compounds that inhibit 
PRMT1 (in vitro IC50 values below 20 µm). After further experiments had 
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AMIs inhibit all arginine methyltransferases that were tested. Assays against 
the lysine methyltransferases Suv39H1, Suv39H2, SET7/9, and DOT1 
demonstrated that only AMI-1 is able to inhibit arginine methyltransferases 
selectively37. 
In 2007, the first target-based approach to inhibitors of histone arginine 
me yltransferase was presented38. Spannhoff et al. created a PRMT1 
homologue model that served as a template for the virtual screening of a 
ompound library. Only the compounds that showed accordance with the 
odel (competition for the substrate, not for the cosubstrate SAM) and that 
mtA and then 
gainst hPRMT1. When tested on HepG2 cells, two compounds, stilbamidine 
an





possessed favorable docking results were tested first against R
a
d allantodapsone (Scheme 1.1), displayed a strong hypomethylating effect. 
Later, the same group also presented the finding of a new lead structure, RM-
65, for the inhibition of RmtA/PRMT1 by means of a fragmentbased virtual 
screen39. 
Heinke et al.40 expanded their virtual and biological screening for novel 
inhibitors. Structure-based virtual screening of the Chembridge database 
comprising 32
fonamides was also found to be active in the micromolar range.  
One of the intriguing yet novel inhibitor is ellagic acid (TBBD) which has 
been found to be specific to CARM1/PRMT4 activity both in vitro and in 
vivo. This inhibitor binds to the enzyme–substrate complex based on the 
substrate sequence and thereby inhibits the enzyme modification on a single 
site alone41. This has not only led to the identification of a novel mechanism of 
enzyme inhibition but also has provided a tool to monitor the single residue, 
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By employing a similar approach, a specific inhibitor of PRMT1 (NS-1) 
has been identified wherein the inhibition of enzyme function is brought about 
by binding to the substrate42
 
Scheme 1.2. Inhibitors of PRMTs trough synthetic optimization.  
 
Compound 7 and compound 8, the most powerful inhibitors of PRMTs of 
that series showed not selectivity between PRMTs and HKTMs.  
.  
1.4.1 PRMTi obtained trough synthetic optimization 
In the last four year a few paper showing compound obtained from 
synthetic optimization has been published (Scheme 1.2). 
Curcumin-like scaffolds with bromo- or dibromophenol substructures, 
obtained from formal simplification of AMI-5, showed an IC50 value up to 14 
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 assay. Subsequent 
synthetic optimization led to the identification of a potent selective inhibitor of 
CARM143. 
Another interesting molecule has been developed in 2009. Starting also in 
this case from a compound obtained by means of high-throughput screening 
and using typical medicinal chemistry approach, Wan et al. identified a good 
inhibitor of CARM-144 with benzoimidazole structure. 
Finally, in 2010, the first selective bisubstrate inhibitor of PRMT-1 has 
been reported. This hybrid between SAM and Arg, showed a good inhibitor 
activity and selectivity45. 
Purandare et al., in 2008, starting from a high throughput screening, 
identified a pyrazole amide derivative and closely related analogs as ‘hits’ 
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2.1 Validating the Hit 
As already mentioned, the first potent and selective PRMTs inhibitors has 
been discovered by Bedford and coll. in 200437. Being interested in small 
molecule modulators of epigenetic targets46 and, particularly, of histone-
modifying enzymes, we focused our attention on AMI structures and noticed 
that all of them were dyes or dye-like derivatives. Particularly, two scaffolds 





Scheme 2.1. Privileged scaffold 
 
The second step was the preparation of a small series of compound 
containing the two scaffolds shown, that was used for biological and virtual 
screening assay. All the data obtained allowed us to describe the binding mode 
of AMI-1 and related compound into the catalytic domain of the PRMT1 
fungal homologue RmtA and more interestingly to understand the AMI-1 

























Figure 2.2. PRMTi binding mode In yellow and cyan are represented the Arg and SAM sites, 
res
s.  
oreover, these analyses hinted that two regions in the RmtA catalytic site, 
the pocket formed by Ile 12, His 13, Met16, and Thr49 (dark gray area in 
Figure 2.3) and the SAM methioninic portion binding site delimited by Arg 
22, Asp44, Gly 46, Cys 47, Ile 51, Leu 52 and Glu112 (light gray area in 
Figure 2.3), should be taken into account when designing novel inhibitors. 
 
pectively. 
An hypothesis for AMI-1 selectivity is displayed in Figure 2.2: the 
compound is docked by the software (Autodock/X-Score) between the Arg 
and the SAM pocket without fully occupy them. On the other hand, AMI-5 is 



















Figure 2.3. The two additional binding pockets in the RmtA catalytic site that emerged from 
three-dimensional QSAR studies. The area highlighted in light gray is delimited by Arg 22, 
As , Gly 46, Cys 47, Ile 51, Leu 52 and Glu 112, whereas the area depicted in dark gray is 
formed by Ile 12, His 13, Met16, and Thr 49. The binding mode of AMI-1 (stick 
rep ntation, carbon atoms in gray) is also shown. 
, before undertaking the exploration of the two aforementioned 
ad
ion 





ditional pockets, we realized that AMI-1 should be optimized as it is likely 
to have low bioavailability and would probably not penetrate the blood–brain 
barrier due to the bisanionic structure. Moreover, it is related to suramin-type 
sulfonated ureas, reported to give pleiotropic interactions with many 
proteins48. 
2.1 Aim of the work 
Therefore, we designed a number of derivatives characterized by the 
substitution of the sulfonic groups with the bioisosteric carboxylic groups, the 
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am ohydroxynaphthoic moiety and the subsequence substitution of the 
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3.1 Synthesis of 7-amino-4-hydroxy-2-naphtoic acid (12a) 
The key step in the synthesis of derivatives showed previously was the 
synthesis of the building block, the 7-amino-4-hydroxy-2-naphthoic acids 
(Scheme 3.1). The synthesis of this building block may seems trivial but it 
isn’t. At that time only failed attempted syntheses of this compound were 
reported49.  
Scheme 3.1. Retrosynthetic approach to the synthesis of PRMTi. 
 
 
So we had to develop a convenient pathway leading to the 7-amino-4-
hydroxy-2-naphtoic acid... 
 We used a Wittig reaction between 3-nitrobenzaldehyde and 
carboxyphosphorane 1050 to regioselectively51 prepare the (E)-
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acetic acid to amino derivative 11b (Scheme 3.2). Ring closure via 
microwave-assisted Friedel–Crafts acylation was followed by hydrolysis of 
Scheme 3.2. Reagents and conditions: (a) benzene, rt, 24 h; (b) Zn (6 mol equiv), AcOH, rt, 
24  (c) AcONa (1.5 mol equiv), Ac2O, MW (300 W, 5 min); (d) HCl 8 N, 5 h. 
 With the mixture of the two isomeric acids in our hands, we turned our 
ingly to what was 
previously reported for similar derivatives49 this task revealed to be not easy. 
After the failure of fractionated crystallization and both conventional and flash 
chromatography, we were able to separate the mixture only through analytical 
RP-HPLC (Fig. 3.1). Unfortunately, this result was not reproducible on a 
pre
 
the crude furnished a mixture of title acids 12a and 12b (1:2 ratio, determined 
by NMR) in a satisfactory 70% overall yield, without intentional purification 









attention to their separation. As a matter of fact, accord
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Figure 3.1 Analytical RP-HPLC separation of isomers 12a and 12b was performed on C18 
column (Vydac 218TP152010) using a gradient of acetonitrile (40–70% acetonitrile in 30 
min) in 0.1% aqueous TFA at 1 mL/min. 
roxyl 













For this reason we decided to investigate if the expected difference in 
reactivity resulting from the relative positions of the amino and the hyd
 reaction of the mixture of ethyl esters 13a and 13b (from 12a and 12b, 
respectively) with CDI in THF at 0 °C for 3 h converted 13b  into the cyclic 
carbamate 14 (Scheme 3.3), leaving 12a unreacted (33% and 55% yield, 
respectively). The two derivatives were easily separated by double extraction 



















12a, 12b; R = H
13a, 13b; R = Et
a
b
13a (33 %) 14 (55 %)
c c










Scheme 3.3. Reagents and conditions: (a) EtOH, H2SO4, reflux, 24 h; (b) CDI, THF, 0 °C, 3 
; (c) HCl 8 N, 5 h. 
heme has been further optimized in our 










his already valid synthetic scT
elating ability; 12a was conveniently obtained by precipitating its 5-amino- 
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3.2.1 Symmetric derivatives 
 The symmetrical ureidic derivative 1a (Scheme 3.5) was directly obtained by 
reacting 13a with diphenyl carbonate in refluxing chlorobenzene in the  
 
cheme 3.5. Reagents and conditions: (a) diphenylcarbonate, DMAP, chlorobenzene, reflux, 
2 h; (b) aqueous NaOH, pyridine, THF, room temp; (c) aqueous NH3, room temp, 12 h; (d) 
h; (h) R1NH2, K2CO3, DMF, 150 °C, 1 h, sealed tube. 















succinyl chloride, TEA, acetone, room temp, 4 h; (e) diethyl malonate, MW (300 W, 30 min), 
neat; (f) 12a, toluene/NMP (10:1), MW (300 W, 3 × 30 min); (g) ClCOCCl3, dichloromethane, 



























































4a, 5a or 6a; R= Et
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 presence of DMAP. The following hydrolysis with aqueous sodium hydroxide 
idic 
derivative . With regard to bis-amidic derivatives, the reaction of  with 
succinyl chloride in the presence of triethylamine in acetone as a solvent 
yielded the ester 3a, which was hydrolyzed to the acid 3b (Scheme 3.5) 
following the aforementioned protocol. On the contrary, the reaction of 13a 
with malonyl chloride in the same conditions failed and the malonyl diamide 
2a was obtained in two steps: 13a (1 equivalent) was first reacted under 
microwave irradiation with an excess of neat diethyl malonate and then a 
second equivalent was added as a solution in N-methylpyrrolidone-toluene 
1:10. Again, subsequent hydrolysis of 2a gave the corresponding acid 2b 
(Scheme 3.5). 
 
3.2.2 Asymmetric derivatives 
The unsymmetrical ureidic derivatives were prepared by treating 13a with 
trichloroacetylchloride in dichloromethane and reacting the resulting 
trichloroacetamide 16 with the proper amine to obtain esteric compounds 4a, 
5a and 6a, the hydrolysis of which yielded the acids 4b and 6b, respectively 
(Scheme 3.5) 
 
3.3 Synthesis of methyl 4-acetoxy-6-amino-2-naphthoate (18) 
The absence of regioselectivity in the preparation of the 7-amino-4-
13a thus requiring its separation from the 5-amino-
and pyridine in tetrahydrofuran furnished the corresponding acid 1b, whereas 
the treatment of the ester 1a with aqueous ammonia gave the bis-am
1c 13a
hydroxy-2-naphthoic ester 
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substituted isomer 13b set hurdles to our intention to build a focused library 
based on this intermediate with the aim of exploring the two aforementioned 
pockets that emerged from computational studies. Therefore, we decided to 
nthesize derivatives the positional isomers of 1a,b, 2a,b and 4a,b, and to 
te their biological activities. 
As a matter of fact, the Wittig reaction between 4-nitrobenzaldehyde and 
carboxyphosphorane 10, followed by the microwave-assisted Friedel-Crafts-
pe ring closure yielded only methyl 4-acetoxy-6-nitro-2-naphthoate 17, 
ptly reduced to the key intermediate 18 by heterogeneous catalytic (palla-






Scheme 3.6. Reagents and conditions: (a) benzene, room temp, 48 h; (b) NaOAc, Ac2O, MW 
00 W, 5 min); (c) H2, Pd/C, ethanol, 2 h 
The reaction of 18 with diphenyl carbonate in refluxing chlorobenzene 
llowed by the hydrolysis of the acetoxy- group with potassium carbonate in 
(3
 
3.4 Synthesis of methyl 4-acetoxy-6-amino-2-naphthoate derivatives 
fo
ethanol as a solvent gave the symmetrical ureidic derivative 7a. The 
subsequent hydrolysis with aqueous sodium hydroxide and pyridine in 
tetrahydrofuran furnished the corresponding acid 7b (Scheme 3.7). On the 
other hand, the unsymmetrical ureidic derivatives were prepared by treating 16 
with trichloroacetylchloride in dichloromethane and reacting the resulting 
crude mixture of the trichloroacetamides 18 with tryptamine to obtain the ester 
9a. The hydrolysis of the latter yielded the corresponding acid 9b. Finally, the 
two-step reaction under microwave irradiation between 18 and diethyl 
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malonate, followed by the hydrolysis of the acetoxy group with potassium 
carbonate in ethanol, yielded the malonyl diamide 8a. Again, subsequent 














Scheme 3.7. Reagents and conditions:  (a) 1) diphenylcarbonate, DMAP, chlorobenzene, 
reflux, 72 h; 2) K2CO3, ethanol, 70 °C, 2 h; (b) aqueous NaOH, pyridine, THF, room temp; (c) 
diethyl malonate, MW (300 W, 30 min), n
× 30 min); 2) K CO , ethanol, 70 °C, 2 h; (2 3 e) ClCOCCl3, dichloromethane, room temp, 4 h; (f) 
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3.5 Indole derivatives 
Once that the biological investigation of the first two series of compound 
was completed (Chapter 4) and our initial hypothesis confirmed, we decided to 
change the naphtholic ring with an indolic one. This idea, due to the 
bioisostery between the system (Scheme 3.7), was supported also by docking 
r library. So, as done for the 6-substituted 
naphthol derivatives, we prepared a pool of compound directly linked to the 














studies. Moreover the indolic ring is easier to synthesize and handle and would 
gave us the chance to build a bigge
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3.5
Compound 26, that can be prepared trough Fisher indole synthesis54, is 
dimerized in presence of trifosgene and triethylamine bearing in high yield 
21a (Scheme 3..8). Applying the same procedure described for the 
naphthalene derivatives, aqueous sodium hydroxide and pyridine in 











Scheme 3.8. Reagents and conditions: (a) trifosgene, TEA, dichloromethane, room temp, 4 h; 
(b) aqueous NaOH, pyridine, THF, room temp; (c) succinyl chloride, TEA, acetone, room 
temp, 4 h; (d) diethyl malonate, MW (300 W, 30 min), neat; (f) 26, toluene/NMP (10:1), MW 
(300 W, 3 × 30 min). 
 
Similarly, compound 22a was obtained by reaction of the aminoindole 26 
with oxalyl chloride and subsequent hydrolysis gave 22b. Compound 27 was 
synthesized by reaction of 26 with neat diethylmalonate by microwave 
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irradiation and intermediate 23a was obtained. Hydrolysis of the latter brings 
to 23b.    
 
3.5.2 Asymmetric derivatives 
The asymmetric ureidic derivative has been synthesized as previously done 
for the naphthalene series. Amine 26 was reacted first with trichloroacetyl 
chloride to yield 28; subsequent reaction of the latter with tryptamine yielded 











Scheme 3.9. Reagents and conditions: (a) ClCOCCl3, dichloromethane, room temp, 4 h; (b) 
tryptamine, K2CO3, DMF, 150 °C, 1 h, sealed tube; (c) aqueous NaOH, pyridine, THF, room 
temp; (d) Boc-Gly-OH, TEA, HOBT, HBTU, DMF/THF, 12h, room temperature; (e) 
















































31a R= Et, X= NO2
32a R= Et, X= H
33a R= Et, X= CH3
34a R= Et, X= OCH3
35a R= Et, X= CN
36a R= Et, X= N(CH3)2
31b R= H, X= NO2
32b R= H, X= H
33b R= H, X= CH3
34b R= H, X= OCH3
35b R= H, X= CN
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Derivatives 31a-36a have been prepared reacting glycine derivative 29b 
with the proper isocyanate and have been subsequently hydrolyzed to 31b-
36b. Reaction between 26 and Boc-Gly-OH in presence of HOBT and HBTU 
as coupling agent brings to 29a; hydrolysis of the Boc protecting group with 
trifluoroacetic acid yield 29b.    
3.6 Indole derivatives, 2nd series 
As emerged from the biological assays (Chapter 4), in the first series of 
indole derivatives we notice a general loss of inhibitor power and an inversion 
in the trend ester-acid; all the ester derivatives results more active than the 
corresponding acid. So we speculate an intramolecular hydrogen bond 
between the carboxylic acid and the NH of the indole that makes both 
functions less available to link the enzymatic pocket. So, supported also by 
energy and stability calculation, we decide to shift the carboxylic acid from 2 
to 3 indole position (Scheme 3.10).  
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3.6.1 Symmetric derivatives 
The optimization of an already reported synthesis allows us to obtain easily 
and with high total yield the methyl 5-amino-1H-indole-3-carboxylate (37). 
temp, 4 h; (d) diethyl malonate, MW (300 W, 30 min), neat; (f) 41, toluene/NMP (10:1), MW 
(300 W, 3 × 30 min). 
 
 A notice has to be done for the hydrolysis of compound 40a which wasn’t 
possible under basic condition. The reaction yield only to the amide bond 
hydrolysis.   
 
All the symmetric derivatives (38a-40a, 38b and 39b) were obtained applying 
the well established procedure already used for the previous indole series 
(Scheme 3.11). 
 
Scheme 3.11. Reagents and conditions: (a) trifosgene, TEA, dichloromethane, room temp, 4 
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3.6.2 Asymmetric derivatives 
pplying the procedure of the 2-substituted carboxyindole compound 43a, 
43b, and 45a-50a were obtained (Scheme 3.12) while 45b-50b cannot be 
recovered through standard basic hydrolysis. For this reason we set up a 
different route for the synthesis of this compound (Scheme 3.13).  
cheme 3.12. Reagents and conditions: (a) ClCOCCl3, dichloromethane, room temp, 4 h; (b) 
yptamine, K2CO3, DMF, 150 °C, 1 h, sealed tube; (c) aqueous NaOH, pyridine, THF, room 
temp; (d) Boc-Gly-OH, TEA, HOBT, HBTU, DMF/THF, 12h, room temperature; (e) 
FA/DMC, 1h, room temperature; (f) isocyanate, TEA, DMC, room temperature, 1-3h.  
 
tert 51 with oxalyl chloride
40b using a mixture of dichlorom
trif  ratio. On the other hand the reaction betwe
d 52a that was then deprotected on the















The reaction of the -butyl ester  in acetone yield 
53 that was easily hydrolyzed to ethane and 
luoroacetic acid 1:1 en Fmoc-
Gly-OH and 51 yielde  amine side with 






                                                                                           Chapter 3: Chemistry 
the proper isocyanate bearing to 55-60. Acidic hydrolysis of the isocyanate 









Scheme 3.13. Reagents and conditions: (a) succinyl chloride, TEA, acetone, room temp, 4 h; 
(b) TFA/DMC, 1h, room temperature; (c) Fmoc-Gly-OH, TEA, HOBT, HBTU, DMF/THF, 
12h, room temperature; (d) DCM/piperidine, 1h, room temperature; (e) isocyanate, TEA, 















                                                                                           Chapter 3: Chemistry 
3.7
selectivity between the 
PRMTs we start thinking about the insertion inside our molecule of chiral 
center. So to improve my knowledge in stereoselective synthesis I’ve been for 
six months at the SCRIPPS research institute, San Diego, CA, in the 
laboratory of Prof. Carlos Barbas, III.  
During this period I’ve been involved in a project aimed to the optimization 
of a highly enantioselective α-amination reactions and to the development of 
new multifunctional alkaloid catalyst.  
3.7.1 Aim of the work 
Recently, Barbas group disclosed a novel, dimeric quinidine catalyst and 
demonstrated its effectiveness in enantioselective aminooxygenation of 
oxindoles.55 This multifunctional catalyst, with its seemingly flexible 1,3-




F gure 3.2. Dimeric quinidine catalyst (a) and (b) aryl oxindole enolates. 
 
N
 The chiral derivatives hypothesis  
Once that also the hydrogen bond was validated (Chapter 4) we found a 
good and easy to handle scaffold for the development of powerful PRMTi. 
With the aim of improve the biological activity and 
dibenzyl tether, was far more effective than other structur
alkaloid dimers tested (Figure 3.2a).  These observations were counterintuitive 
 a catalyst design perspective and prompted us to explore the use of this 
yst in other asymmetric transformations, particularly in enantiose


















C3 flanked by two
aryl substituents 3
(a) (b)
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These reactions would provide access to optically active 3-amino aryl 
oxindoles, common structural motifs present in a variety of bioactive 
molecules, including NITD609 and  SSR-149415, which are drug candidates 
for the treatment of malaria and stress-related disorders, respectively56. 
To date there was no general catalytic method for the asymmetric synthesis 
 those with readily cleavable diazo 
es arise when oxindoles bear an aryl substituent at the C3 
osition.  First, the aryl group renders the C3 methine acidic, facilitating a 
ba
b).   
 
3.7.2 Optimization of reaction conditions 
using phenyl oxindole 61a and di-tert-butyl 
azodicarboxylate was examined in the presence of cinchona alkaloid catalysts 
(Fi
oquinidine dimers IV and 
V also catalyzed the α-amination and provided products in moderate yields 
with low ee (entries 4-5).  Interestingly, these dimers were not as effective as I 
(entry 1 vs. entries 4-5). Previously developed dimeric catalysts VI-VIII from 
Barbas laboratory were also tested, but they did not give satisfactory results 
with respect to ee (entries 6-8). These catalysts were synthesized by 
dimerization of quinidine at the C9 position using different dibromo benzyl 
linkers.  Notably, catalyst VII with a free hydroxyl group at C6 provided 
of 3-amino aryl oxindoles, especially
compounds such as di-tert-butyl azodicarboxylates56c, 57.  
Several challeng
p
ckground reaction to occur. Conversely, it sterically hinders this position 
thereby limiting reactivity.  Finally, it is difficult to differentiate the two 
enantiotopic faces of the oxindole enolate at C3 when this position is flanked 
by two aryl groups of a similar size, one of which is the aryl oxindole ring 
(Figure 3.2
Initially, a model reaction 
gure 3.3, Table 3.1).  With 10 mol % of monomeric quinidine-derived 
catalyst I, II, or III, the α-amination reaction proceeded smoothly at -20 °C to 
afford product 63a in good yields, albeit low enantiomeric excess (ee) (entries 
1-3).  Similarly, commercially available bulky hydr
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product in higher ee than did catalyst VI (entry 7 vs. entry 6). The catalyst 
with the 1,3-dibenzyl linker was more effective than that with the 1,2-dibenzyl 
linker (entry 8 vs. entry 6).  Not surprisingly, C-6 quinidine dimer IX (5 mol%) 
was most effective among the catalysts examined. These results mirrored those 
obtained from previously reported catalytic, enantioselective 










oderate enantioselectivity obtained with catalyst IX warranted further 
investigation.  We discovered that Boc-protected aryl oxindole 1a was highly 
reactive and a competing nonselective reaction occurred (due to the inherent 
reactivity of aryl oxindoles), thereby compromising the enantioselectivity. 
This problem was solved by performing the α-amination reaction at low 
temperature (entry 9 vs. entry 10).  However, the ee increased only marginally 
when the temperature was lowered from -50 °C to -70 °C (entry 10 vs. entry 
11).   
A survey of solvents resulted in conditions that provided excellent yield and 
ee: the optimal results were obtained when the α-amination was performed in 








(DHQD)2PHAL, VR = Me, I








R = Me, VI (1,3 linker)
R = H, VII (1,3 linker)
R = Me, VIII (1,2 linker)
9
C6-dimer (1,3 linker)
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ensure good yield and ee of the desired product (24 h, entry 14 vs. 48 h, entry 
15). As previously observed, the free hydroxyl groups in catalyst IX were 
important for high yield and enantioselectivity (entry 15 vs. entry 17).  These 









Table 3.1. Optimization studies. Unless otherwise noted, all reactions were run for 24 h. 
Reactions in entries 1-8 employed 10 mol% catalyst; those entries 9-17 employed 5 mol%. [a] 




dicarboxylate electrophile via weak hydrogen bonding before C-N bond 














1 I THF -20 86 45 
2 II THF -20 74 27 
3 III THF -20 81 14 
4 IV THF -20 77 0 
5 V THF -20 51 35 
6 VI THF -20 96 5 
7 VII THF -20 94 41 
8 VIII THF -20 84 35 
9 IX THF 
10 IX THF -50 
-20 93 53 
87 83 
11 IX THF -70 78 88 
12 IX CH2Cl2 -70 89 79 
13 IX Et2O -70 72 92 
14 IX toluene -70 87 95 
15c IX toluene -70 93 98 
16 IX m-xylene -70 73 83 

















24 - 48 h
c
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3.7.3 Investigation of oxindole substrates 
Having established the optimal reaction conditions, we began to investigate 
the scope of the α-amination reaction with respect to oxindole substrates 
as general in scope, tolerating aryl oxindoles of 
dif












Table 3.2. Enantioselective α-aminations of aryl oxindoles. [a] Isolated yields. [b] 
Determined by chiral HPLC analysis. 
 
 is noteworthy that oxindole 63f, which contains a fluorine atom, was 
obtained in good yield and high ee (entry 6).  Enantiomerically enriched 
Entry
(Table 3.2).  The reaction w
ferent electronic natures and with different aromatic substitution patterns.  
For example, oxindoles bearing electron-neutral and electron-rich substituents 
at C5 afforded the desired products in excellent yields and ee’s (entries 1-2).  
Moreover, reactions with substrates with various aryl groups at the C3 position 































1 H H 3a 93 98 
2 OMe H 3b 96 95 
3 H 4’-Me 3c 71 96 
4c H 3’-OMe 3d 95 97 
5 H 4’-tBu 3e 76 96 
6 H 4’-F 3f 87 96 
7 OMe 4’-Me 3g 94 98 
8 OMe 3’-OMe 3h 92 97 
9 OMe 4’-F 3i 91 73 
10 OCF3 3’-OMe 3j 93 93 
11 F 3’-OMe 3k 87 87 
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syntheses of fluorine-containing molecules are of importance in drug 
discovery and development. 
Under our optimized conditions, oxindoles with various substituents at C5 
and different substitution patterns on the C3 substituted aryl ring were all 
yields and ee’s of the desired products 
ost of these substrates. The absolute configuration at the newly 
created center was determined to be R by comparison with a known oxindole 
derivative of 63a. Finally, we demonstrated that product 63a could be 











Table 3.2. Insight into the role of the dimeric structure. [a] Isolated yields. [b] Determined 
by chiral HPLC analysis. 
 
viable substrates (entries 7-11).  The 
were high for m
converted into the corresponding, free amino aryl oxindole in good yield with 













1 IX 3a 93 98 
2 XI 3a 94 98 
3 XII 3a 89 98 
4 XIII 3a 89 94 









cat (5 mol %)
NBoc
1a 3a
toluene, -70 oC, 48 h
NHBoc
R = quinidine( IX)
N
R =
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To determine the role of the dimeric structure and the quinidine units in 
catalysis by IX, analogues were synthesized and examined in the 
enantioselective R-amination of 1a (Table 3.3).  
Catalysts XI and XII had only one quinuclidine moiety within the catalyst 
molecule. In XI, the 1,3-dibenzyl linker was attached to an electronrich π-
quinoline ring, and in XII, it was attached to a simple phenyl ring. If π-π 
interactions between the two quinoline units in IX and XI were critical for 
catalysis, one would expect that XII would be a less effective catalyst. In 
catalyst XIII, the linker was a single benzyl group. The molecular weight and 
complexity of catalyst IX is greater than those of analogues XI, XII, and XIII. 
Significantly, catalysts IX, XI, and XII provided the desired product in similar 
yields with excellent ee’s (Table 3.3, entries 1-3). Interestingly, when 
monomeric catalyst XIII was used, the ee was lower (entry 4 vs. entries 1-3). 
The drop in ee was even more significant when the 1,3-dibenzyl linker was 
replaced by a methyl group in catalyst I (entry 5). The effects of the C6-
alcohol protecting group on ee were striking. This effect was not expected as 
this group is distal to the quinuclidine nitrogen atom where the reactive 
oxindole enolate is presumably generated. These observations provide 
valuable information that will aid future catalyst design and development. Our 
hypothesis is that the hydroxy protecting group at C6 affects the conformation 
of quinidine; this conformation impacts the stereochemistry-determining step 
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  ‐ 54 ‐     
 
B), (b) the free hydroxyl group at C9 to ensure high yield and ee, and (c) the 
sam
 
talyst XII (B and C)58. 
Our proposed transition state structures are consistent with the following 
experimental observations: (a) the importance of a π-rich moiety that protects 
the C6 hydroxyl group in the catalyst to maintain high selectivity (Figure 3.4 
e sense of asymmetric induction is observed for both aminooxygenation 
and R-amination of oxindoles58. 
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4.1 Biological evaluation of naphthalene derivatives 
In accordance with previous reported data by our research group46b, 47, we 
first performed a preliminary screening of the activities of compounds 1–9 
against Aspergillus nidulans RmtA, a fungal PRMT acting on histone H4 
substrate and validated by us as a useful, predictive model for studying PRMT 
inhibition in mammals. Then we tested the derivatives against human 
NA-
 sequence similarity to human PRMT1 
and specific for methylation at Arg 3 of histone H415a, and against hPRMT1, 
using core histones as substrate as previously reported15a, 47. The inhibition (%) 
recombinant PRMT1 in vitro, using histone as well as nonhistone (the R
binding nuclear shuttling protein, Npl3) proteins as a substrate, to confirm 
their inhibitory activity and to observe the influence of substrates different 
from histones on the inhibitory activity. Subsequently, selected compounds 
were tested (50 µm) against a panel of human PRMTs (PRMT1, PRMT3, 
CARM1, and PRMT6), using histone H4 (for PRMT1), histone H3 (for 
CARM1 and PRMT6) or GAR (for PRMT3) motifs as substrates. 
Furthermore, to assess the selectivity of our compounds against lysine 
methyltransferases, we also tested our compounds against the HKMT SET7/9 
using histone H3 as a substrate.  
All the biological assays have been performed by Prof. Gerald Brosch 
(Division of Molecular Biology, Biocenter-Innsbruck Medical University) and 
Prof. Mark T. Bedford (University of Texas M.D. Anderson Cancer Center 
Science Park-Research Division Smithville, Texas, USA). 
 
4.1.1 Inhibitory activities against RmtA and PRMT1 
Compounds 1-9 were preliminarily tested against Aspergillus nidulans 
RmtA, a fungal PRMT with significant
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at a fixed dose (nearly 100 µm) were first determined, and then the IC50 values 
for the active compounds were established (Table 4.1). Moreover, the 
derivatives were also tested against hPRMT1, using the heterogeneous nuclear 
ribonucleoprotein (hnRNP) Npl3p, an in vivo substrate of HMT1 from 
Saccharomyces cerevisiae59, as a substrate. The inhibition (%) at fixed doses 
(10 and 50 µm) was determined (Table 4.2). AMI-1 was used as reference 
compound in both assays. 
irst result that emerged from both assays was that the substitution of 
the AMI-1 sulfonic group with its carboxylic isoster gave only a slight 
decrease in inhibiting activity (cf. AMI-1 and 1b, Tables 4.1 and 4.2). 
C nt of the carboxylic group with an ester or an amide 
fun
detrimental to the inhibitory potency of the resulting derivatives, with the 
f compounds 1b, 2b and 3b). 
The f
onversely, the replaceme
ction diminished the activity against PRMT1. There was no difference in 
the order of activity when histone or nonhistone proteins were used as the 
substrate (1b>1c>1a), however, a slightly different order resulted when 
compared to the results obtained against RmtA (1b>1a>1c).  
The substitution of the ureidic group with bisamidic moieties was 
decrease being proportional to the length of the aliphatic spacer (cf. inhibition 
(%) values o
The introduction of the tyramine nucleus in place of one of the two 
naphthalenic moieties resulted in derivatives with activities comparable to 
those of their counterparts (cf. activities of 1a and 4a, or 1b and 4b). On the 
other hand, replacement with the isosteric indole-2-carboxylic moiety gave 
less homogeneous results. In fact, indolic derivatives 6a and 6b showed 
decreased RmtA inhibition (Table 4.1) in comparison with their naphthalenic 
counterparts 1a and 1b, respectively, but the activities against PRMT1 were  
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Ta le 4.1. Inhibition activities (IC50) of 1-9 against hPRMT1 and RmtA using histone 
substratea,b. aChicken erythrocyte core histones were used as substrate; bValues are means 






R1 R2 or % inhbtnX Y Z 
IC50 (µM) 
  Rmt PRMT1 A 
1a OH  OOEt - - 1 448 H C H 19  
1b OH  OOH - - 38 298 
c OH  NH2 - -  406 
 OH  OEt -CH2- - 21 233 
b OH  OH H -CH2- - c NDc 
3a OH  OEt 2CH2- - 272 676 
b OH  OH 2CH - 123 343 
 OH  OEt - 
H C H 1  
1
2a
H CO H 445
H CO H 1  
2 H CO ND
H CO H -CH  
3 H CO H -CH 2-
4a H CO H 196  
4b OH  OH - 
 346
H CO H 170  
a OH  OEt - 
 262
5 H CO H 180  
a OH  OEt - 
 875
6 H CO H 620  
6b OH  OH - 
 510
H CO H 330 0 at 230 μM 
a H COOMe H - - 04 195 
H COOH H - - 5 112 
a H COOMe H -CH2- - 05 133 
H COOH H -CH2- - 95 272 
9a H COOMe H  
 




 OH 2  
8b OH 3  
 OH 290   320
9b H COOH H OH  227 205 
AMI-1 OH H SO H H - - 883 d d92  
b
determined for at least two separate experiments; cN
µm (RmtA) and 1.2±0.5 µm (PRMT1), fluorescence
 
similar (Table 4.1 and Table 4.2). Strangely, in this case, carboxylic acid 6b 
was less active than the corresponding ester 6a.  
 




































Com. W X Y Z 










  50 μM 10 μM 
1a OH H COOEt H - - 40.81 4.91 
1b OH H COOH H - - 75.16 41.73 
c OH H CONH2 H - - 63.47 0.13 
a OH H COOEt H -CH2- - 34.65 10.77 
b OH H H H 2 21.73 
 OH H COOEt H 
-
2CH2-
- 31.66 0.92 
OH H C O  
-
H2-
- 5 -0.41 
 OH H E H
1
2
2 COOH -C 2- - 60.2
3a
CH
3b O H H CH2C
30.8
4a COO t  - 61.24 30.21 
4b OH H C OH HO   - 71.65 20.21 
a OH H C5 OOEt H - -7.20 -1.70 
a OH H C6 OOEt H - 53.20 27.73 
6b OH H C O   O H H - 32.47 8.01 
a H COOMe - 7 19.62 
- 1  
b H COOH H OH -CH2- - 90.99 -8.59 
9
7 H OH - 59.0
7b H COOH  75.29 
8a H COOMe H OH -CH2- - 52.07 25.13 
H OH - 00.00
8
a H COOMe H OH  83.78 20.47 
9b H COOH H OH  73.17 20.15 
AMI-1 OH H SO3H H - - 100.00 66.89 
Table 4.2. Inhibitory activities of com
substratesa,b. aNpl3p was used as 
pounds 1–9 against hPRMT1 using nonhistone 
a nonhistone substrate, SAM as a cofactor. bValues given 
are means determined for at least two separate experiments. 
 
This outcome could be justified by the formation of an intramolecular H 
bond between the indole NH and the COOH group, thus reducing the 
availability of both groups for interaction with the binding pocket of the 
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enzyme. Regarding compounds resulting from the formal shift of the ureidic 
function from the C-7 to the C-6 position of the naphthalene ring, it is 
noteworthy that their inhibitory activity was greatly enhanced. In fact, 
compounds 7, 8, and 9 were more potent than their positional isomers.  
igure 4.1. Effects of compounds on cellular arginine methyltransferase activity: a) a 
pl3. Three hours post-transfection, the cells were incubated with the 
indi ated compounds for 24 h. The cells were lysed in RIPA buffer, and Western analysis was 
per
eff












depiction of the GFP–Npl3 fusion protein with the position of methylated region and the 
antibodies that recognize it; b) HeLa cells were grown in 12-well plates and then transiently 
tran fected with d2GFP–Ns
c
formed with either the 1E4 antibody (top panel) or aGFP antibody (bottom panel). The 
ects of the compounds on GFP-Npl3 methylation status were established with the methyl-
specific antibody, 1E4. The aGFP antibody showed the protein levels of GFP-Npl3. DMSO 
(0.25% v/v) was used as a vehicle (lanes 1, 4, 7, 11); compounds concentrations: AdOx (10 
and 20 µm, lane 2,3), AMI-1 (10 and 100 µm, lanes 5,6), 7
 
Moreover, the biscarboxylic acid derivative 7b, the isomer of 1b, showed 
the highest inhibitory efficacy, comparable (Table 4.1) or even better (Table 
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4.2) than AMI-1. Finally, the introduction of a tertiary amine, like the 
dimethyl-aminopropyl moiety in compound 5a, led to a substantial decrease of 
the inhibitory potency against hPRMT1 (Table 4.2). To determine whether the 
compounds that showed arginine methyltransferase inhibitory properties were 
able to inhibit PRMT activity within a cellular context, we used a fusion 
between green fluorescence protein (GFP) and the yeast protein Npl3. We 
previously established that mammalian PRMT1 can methylate Npl3 in vitro, 
thus we reasoned that this reaction could also take place within a mammalian 
cell line. A destabilized GFP variant was used that displays rapid turnover 
rates. This shorter half-life makes destabilized variants suitable for use in 
quantitative reporter assays. The GFP–Npl3 was transiently transfected into 
HeLa cells; post-transfection the cells were treated for 24 h with derivatives 
1b, 7b, 8b and 9b (10, 50, and 100 µm), using AMI-1 and 2’,3’-
acycloadenosine-2’,3’-dialdehyde (adenosine dialdehyde, AdOx), an indirect 
methyltransferase inhibitor, as reference compounds.  
Because GFP and Npl3 are fused, the aGFP antibody was used to establish 
equal loading and aNpl3 antibody (1E4) acted as the methylation sensor 
(Figure 4.1a). Thus, the relative degree of arginine methylation in the presence 
of the different inhibitors can be established. Using this assay system we 
demonstrated that all tested derivatives were able to inhibit methylation of the 
GFP-Npl3 fusion, even if to varying extents. We thus focused our attention on 
7b
7b inhibited the methylation of Npl3 
 cell in a dose-dependent manner and more effectively than the 
, the compound that showed the highest inhibitory efficacy in enzymatic 
assays. A concentration gradient of 7b (10, 50, 100 µm) was used to treat 
GFP–Npl3 transiently transfected HeLa cells for 24 h, using AMI-1 (10 and 
100 µm) and AdOx (10 and 20 µm) as reference compounds. Total cell 
extracts were then subjected to Western analysis with aGFP and 1E4 (methyl-
sensitive aNpl3) antibodies. Derivative 
within the
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reference AMI-1 (Figure 4.1b). In addition, the inhibitor of global 
methylation, AdOx, also reduced the methylation status of this reporter. 
4.1.2 Inhibitory activities against a panel of arginine methyltransferases 
The most active derivatives were selected and tested at 50 µm against a 
panel of arginine methyltransferases, as well as against a lysine 
methyltransferase, to assess their selectivity. Compounds 1b, 1c, 2b, 4a, 4b, 
7b, 8b, 9a, and 9b were tested against the human recombinant arginine 
methyltransferases PRMT1, PRMT3, CARM1 and PRMT6, using histone H4, 
GAR motifs and histone H3 (for both CARM1 and PRMT6) as substrates, 
respectively, and also against the lysine methyltransferase SET7/9, using 
histone H3 as a substrate. AMI-1 was used as reference compound in all 
assays. As seen in Table 4.3, all of the derivatives tested are generally more 
selective for arginine methyltransferases than AMI-1. In fact, they are 
practically inactive against the lysine methyltransferase SET7/9, whereas 
AMI-1 shows a minor inhibition of this HKMT enzyme. This, together with its 
capability to inhibit all tested PRMTs, support the pleiotropic nature of the 
interactions established by the sulfonic groups. In contrast, compound 1b, the 
fairly comparable to that of its sulfonic counterpart against PRMT3, and to a 
lesser degree against CARM1. Interestingly, the use of histone H4 instead of 
core histones or the nonhistone protein Npl3p as a substrate for the PRMT1 
assay yielded an appreciably weaker inhibition of PRMT1. The malonic 
bisamidic derivative 2b exhibited a similar activity profile against the enzyme 
panel (Table 4.3). The bisamide 1c was consistently less active than 1b and 2b 
against both PRMT3 and CARM1, but was the only compound among those 
tested that was able to inhibit PRMT6, with potency comparable to that of 
AMI-1 or even higher. Regarding compound 7b, the positional isomer of 1b, 
this compound was confirmed as the most active in the series showing very 
carboxylic analogue of AMI-1, is inactive against SET7/9 but its activity is 
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good inhibitory activities against PRMT1, PRMT3, and CARM1, and was 
comparable or even better than that exhibited by AMI-1. However, it was 
practically inactive against both PRMT6 and SET7/9 (Table 4.3). The 
bisamidic malonic analogue 8b was consistently less active than 7b against 
both PRMT1 and PRMT3, yet displayed a positive modulating effect on the 
enzymatic activity of CARM1 (Table 4.3). Similarly, the tryptamine 
derivatives 9a,b showed little or no activity against PRMT1, PRMT3 and 
PRMT6, but strongly increased enzymatic activity of CARM1. In contrast, the 
isomeric derivatives 4a,b showed only weak inhibition against all enzymes. 
Com. W X Y Z R1 R2 












1b OH H COOH H - - 12.36 90.92 53.06 -7.23 -8.07 
1c OH H CONH2 H - - 42.42 29.46 9.26 43.77 13.36 
2b OH H COOH H -CH2-
- 48.44 91.94 54.96 6.40 -1.40 
4a OH H COOEt H - 24.73 42.13 -46.56 -12.40 6.65 
4b OH H COOH H - 9.86 13.98 39.53 18.30 -5.13 
7b H COOH H OH - 61.65 72.81 83.07 -21.72 3.80 
8b H COOH H OH -CH2-
- 16.76 32.56 -298.99 -2.09 14.44 
9a H COOMe H OH  
- 
20.50 -5.03 -328.49 9.70 -8.46 
9b H COOH H OH  38.89 -8.17 -217.98 -11.13 -10.41 
AMI-1 OH H SO3H H - 87.67 101.33 74.76 40.69 34.34 - 
Table 4.3. Inhibition activities of selected compounds against different methyltransferases.a  
aValues given are means determined for at least two separate experiments; bHistone H4 (1.5 
µm) and SAM (0.42 µm) were used as substrates; cGlycine- and arginine-rich (GAR) motifs 
(0.41 µm) and SAM (0.42 µm) were used as substrates; dHistone H3 (1.1 µm) and SAM (0.42 
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.2 Biological evaluation of indole derivatives 
4.2.1 Inhibitory activities against PRMT1 
Compounds 21-23, 30, 38-40, 43, were preliminarily tested against 
hPRMT1, using the heterogeneous nuclear ribonucleoprotein (hnRNP) Npl3p, 
an in vivo substrate of HMT1 from Saccharomyces cerevisiae59, as a substrate. 
The inhibition (%) at fixed doses (10 and 50 µm) was determined (Table 4.4). 
AMI-1 was used as reference compound in both assays. 
 
Com X Y R1 R2 % inhib hPRMT1/Npl3 
4





50 μM 10 μM 
21a COOEt H 32.16 10.10 - - 
21b COOH H 19.84 -21.68 
22a COOEt H -CH2- - 61.63 1.45 
22b COOH H -CH2- - 70.59 0.00 
23a COOEt H -CH2CH2- - 17.01 -22.16 
23b COOH H -CH2CH2- - -17.21 -32.19 
30a COOEt H - 
- - 
42.02 -6.27 
30b COOH H - 9.93 -2.36 
31a COOEt H - 63,21 6,70 
38a H COOMe - - 58,82 17,64 
38b H COOH - - 82,35 70.59 
39a H COOMe -CH2- - 88.24 64.71 
39b H COOH -CH2- - 94.12 47.06 
40a H COOMe -CH2CH2- - 29.41 -11.76 
40b H COOH -CH2CH2- - 70.59 64.71 
43a H COOMe - 47.06 0.00 
43b H COOH - 82.35 0.00 
AMI-1 - - - - 100.00 66.89 
7b - - - - 100.00 75.29 
Table 4.4. Inhibitory activities of compounds 21-23, 30, 38-40, 43 against hPRMT1 using 
nonhistone substratesa,b. aNpl3p was used as a nonhistone substrate, SAM as a cofactor. 
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The data emerging from the first series of indole derivatives (21-23a,b and 
30a,b) were not exciting (Table 4.4). To a first look all the derivatives result 
olecular 
y all the 3-substituted carboxyindol 
are
depending manner. 
The spacer has to be one CH2 (39b>38b>40b). Again the asymmetric 
derivatives show almost the same power of the symmetric ones (cf. activities 
 shows an inhibitor 
power sim
less active of the corresponding naphthalene analogue.  
The most important data is a general inversion of activity trend between 
ester and acid. In the 1st  indole series the ester derivatives result more active 
than the corresponding acid (21a>21b, 23a>23b and 30a>30b). On the other 
hand, in contrast with the naphthalene data (Table 4.2), the substitution of the 
ureidic moiety with a bisamidic one bring to an improvement of activity 
(21a<22a) that dramatically drop with the increase of the spacer length 
(22a>23a). Asymmetric derivative obtained by substitution of the aminoindole 
with the tyramine nucleus bring to a slightly increase of activity in the ester 
derivatives (cf. activities of 21a and 30a) while the relation is the opposite 
looking at the acid (21b>30b). Notably mixed amid-urea derivative 31a 
showed a nice inhibitor power, being the most active compound of this series.  
As regards to the 2nd indole series, our hypothesis of intram
hydrogen bond seems to be valid. Not onl
 better PRMT-1 inhibitors, in this assay, than the 2-carboxy ones but also 
the activity trend between ester and acid has been recovered (Table 4.4). As 
the previous compound the replacement of the ureidic function with a 
bisamidic one improve the PRMT-1 inhibition in a length 
of 38b and 43b). Moreover, the bisamidic derivative 39b
ilar to AMI-1 and 7b, our best inhibitors. 
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 4.2.2 Inhibitory activities against a panel of arginine methyltransferases 
Applying the same procedure developed for the naphthalene derivatives53, 
the most active indole compound were selected and tested at 50 µm against a 
panel of arginine methyltransferases, as well as against a lysine 





 X Y R1 R2 
% inhib at 50 μM  




and PRMT6) as substrates, and also against the lysine methyltransferase 
Com
thyltransferases.a  aValues given are means determined for at least two separate 
eriments; bHistone H4 (1.5 µm) and SAM (0.42 µm) were used as substrates; cGlycine- 
and arginine-rich (GAR) motifs (0.41 µm) and SAM (0.42 µm) were used as substrates; 
dHistone H3 (1.1 µm) and SAM (0.42 µm) were used as substrates 
 
Compounds 38b, 39a, 39b, 40b, 43b and 31a were tested against the 
human recombinant arginine methyltransferases PRMT1, PRMT3, CARM1 















38b H COOH - - -20.89 59.83 nd nd -8.07 26.10 
39a  
39b nd 56.78 -3.41 




AMI 101.3 74.76 40.69 34.34  
H COOMe CH2 - 6.61 75.54 nd nd 70.73 28.83
 H COOH CH2 - -9.38 80.97 nd 
2 2
H COOH -  -66.19 72.84 nd nd 61.70 -3.79
COOEt H -  27.73 55.89 -377.12 -19.49 10.25 nd 
- - - - 61.65 72.81 83.07 -21.72 3.80 nd
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SET7/9 and G9a, using histone H3 as a substrate. Data quantization has been 
done by liquid scintillization counting or densiometric measurement (Quantity 
One Software). Where not showed, the data does not fit with measurement on 
film (Figure 4.2 and Figure 4.3). 
 
Fi  4. ibi  acti se s aga t CARM-1/H3 
Fi  4.3 h ivit f selected com s aga t PRM 3 
 the selectivity assays of the indole 
derivatives is a good inhibition of PRMT3. Derivatives 38b, 39a, 39b, 40b at 
50 µm in i  on R  amo g the PRMTs. O
e th  the ref nce 7 wards rent 
selectivity between lysine 










gure . In ibition act ies o pound ins T-6/H
 
The first important result emerging from
hib t almost ly P MT3 n n the other hand the 
same compounds are less selectiv an ere b to diffe
methyltransferases. Seems that the indole structure, strictly linked to the SAM, 
bring to a decrease of selectivity. Interestingly 39b and 40b, the most powerful 
inhibitors of the indole series, show a good 
on G9a/H3. 
   N      P I1 31a  1c    39b        D       AM 40b
40b   39b    1c 1a AM   P      D        N        3 I1
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4.2.2 Activation activities against a panel of arginine methyltransferases 
Another important results emerging from the selectivity assays is the 
peculiar activity of 31a: this compound, almost inactive towards PRMTs, 
shows a really strong and selective activation of CARM-1. This data, reported 
for the first time in literature and that may seems an outlier, bring us to build 
all focused library of compound ctl
validate our hypothesis (Table 4.6). 
tiva  of C  on of hPRMT1 a 3 ) and 
ent substrate, one 
histonic and one non-histonic. Regards to the H3 substrate the better activator 









and test a sm  stri y correlated to 31a to 
 
Table 4.6. Ac tion ARM-1 and inhibiti Histone H (1.1 µm










μM 10 μM 50 μM
a 50 μMb 
t H O2 6,70 0 
 
63,21 31a COOE N   184,37 175,5
31b COOH H NO2 0.  0.00 142,54 85,29 
t H  0,0 0,00  
32b COOH H H 4,74 3,68 166,09 171,76 
t H H3 11,5 0,00 5 
33 3 00 0,00 11 2 
t H H 6,8 0,00 1 1 
 H H 37,8 0,00  
t H N 13,6 0,00 5 
 H N 4,7 0,00 8 
3 COOEt H ,3  0,00 10 9 
C (CH 6,6 0,00 1 
e NO 41,1 23,5 1 
e H 0,00  
e CH 1 0,00  
e CH 1 0,00 4 
e CN 0.0 0.00  
5  COOMe H3 2 41 0,00 12  
     
      
00 















































2 45a H COOM 8 3 133,98 114,7



































SAM (0.42 µm) were used as substrates, bPABP (1.1 µm) and SAM (0.42 µm) were used as 
substrates.  
The value of activation has been measured on two differ
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An interesting result is the inversion of activity between ester and acid. For 
the activation the better compounds are all ester, while the acid works better 
for the inhibitions. Moreover all the 2-substituted carboxyindole are better 
activator than 3-derivatives, while for the inhibitors was the exact opposite (cf. 
activity of 31a, 33a and 35a, with 45a, 47a and 49a). For the further 
development of activators the substituent on the phenyl ring has to be taken in 
account. An electron poor ring is needed to improve activation of CARM1 
(35a and 31a are better than 32a and 36a) as well as a para-substitution 
(compare 33a and 32a).  
The activation data became more interesting if consider that DMSO alone 
inhibits the substrates methylation of about 2.5-3 fold.  




Figure 4.4. Dose response data of 31a on CARM1/PABP 
 
A strong activation effect (200%) starts already at 3µm and increase until 
360% at a dose of 100 µm. Additional studies are on run to determine the 
AC  (activator concentration at 10% maximal activation level)60 31a.  10
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As
the
 previously done with the best PRMTi, also for compound showing the best 
activator power (33a and 35a) in cell assays has been done.  
In this case as substrates PABP-1 has been used because CARM-1 doesn’t 
methylate NPL3.  Importantly, CARM1 is the only enzyme that methylates 
PABP1, and in CARM1 knockout cells PABP1 is hypomethylated. For this 
study, a methyl-specific antibodies against the PABP1 sequence 
CGAIR*PAAPR*PPFS (where R* represents an asymmetrically dimethylated 
arginine residue) has been developed. Moreover,  as yet, no arginine deme-
thylases have been discovered, this methyl-mark is thus extremely stable. To 
test the efficacy of potential PRMT modulators in cells could require days of 
treatment to allow for the methylated substrates to turnover. Under these 
conditions, compounds with pleiotropic effects would be difficult to 
investigate in a cell-based assay. To bypass this problem a PABP1 inducible 
cell line has been developed. Upon treatment with tetracycline (Tet), these 
HEK293 cells express a flag-tagged form of full-length PABP1 (fPABP1). 
This tag allows the induced form of PABP1 to migrate more slowly by SDS-
PAGE. We can, thus, easily distinguish between the endogenous PABP1 and 
 newly synthesized fPABP1. When fPABP1 expression is induced with Tet 
in the presence of a potential CARM1 activator, we can gauge the degree of 
fPABP1 methylation, using the methyl-specific anti-PABP1 antibody.  
As can be easily seen (Figure 4.5), 33a and 35a induce a strong increment in 
methylation of newly synthesized PABP-1 (higher bands). So our activators as 
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Tetraciclin (1 µg/ml) 
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5.1 Docking and binding mode of naphthalene derivatives 
The binding modes of selected PRMT inhibitors were carried out in an 
attempt to rationalize their differences in terms of activity. To this aim, 
compounds 1b, 7b, and AMI-1 were docked (Autodock 3 program)61 into the 
homology model of the PRMT1 orthologue RmtA, previously reported by us47 
(a) 
molecules 
by the X-Score  external scoring function showed that 1b belongs to the DSP 
group, while 7b seems to bind preferentiall igure 5.1). In
artic r, the nding nfo tion selected for s on
observed for the SAM co-factor (F 5.2). In fact, one naphthalenic group 
ays i  sa wic ik d  chai
deni bin e) ing osit a Waa ntera ns, t
corresponding carboxylate group makes a weak hydrogen bond with Thr126-
OH. The other aromatic moiety is placed in the SAM methionine pocket, 
delimited by Arg22, Asp44, Gly46, Cys47, Ile51, Leu52 and Glu112, and the 
respective carboxylate function establishes either an electrostatic or a 
. Moreover, the two 
ureidic NH are within hydrogen bonding distance of Asp68 carboxylate group 
(Figure 5.2B), thus mimicking the two OH of the SAM ribosyl moiety 




and used to describe three different binding modes of PRMT inhibitors: 
docked in the Arg pocket (DAP), (b) molecules docked in the SAM 
pocket (DSP), and (c) molecules partially overlapping with both sites (docked 
in both pockets, DBP).47 The analysis of the Autodock conformations selected 
62
hydrogen bond interaction with the Arg22 side chain
y in the DBP (F  
p ula  bi  co rma 1b is imilar to the e 
igure 
l n a nd h-l e mode between Met69 and Met123 si e ns (SAM 
a ne ding sit  mak  p ive v n der ls i ctio while he 










e described for its positional 
isomer 1b, as the binding conformation selected by X-Score was docked into 
the DBP pocket (Figure 5.3). Significant hydrogen bonds may be observed 
between 7b with both the arginine anchoring residues Glu112 and Glu121 and 
with Asp68 (Figure 5.3B). The differences in affinity values among 
derivatives structurally highly correlated to each other (like 1b, 7b and AMI-
1) could be better highlighted by the direct comparison of their respective 
and by comparison of the bonding interactions (listed in Table 5.1) made by 








Figure 5.1 Autodock/X-Score selected binding conformations of compounds 1b 
(orange), 7b (green) and AMI-1 (magenta) docked into RmtA catalytic site. The volumes 
occupied by Arg and SAM are represented in yellow and cyan, respectively 
 
Regarding derivative 7b, it is noteworthy that it displays a substantially 
different binding scenario from the one abov
binding modes while maintaining the same protein orientation (Figure 5.4), 
 the residues in RmtA binding pockets
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Figure 5.2 Comparison between binding conformations of SAM cofactor and compound 
1b into RmtA catalytic site. A) SAM cofactor (cyan colored carbon atoms); B) 1b (orange 
colored carbon atoms). The RmtA residues within 4.0 Å from the docked compounds are 
rep ed in green. For the sake of clarity, hydrogen atoms are not displayed. 
 
Like AMI-1, derivative 7b can be classified as a DBP binding compound, 
 to 
bin
binding derivative and thus shares fewer 
int  than 7b does. Interestingly, the binding profile of 1b 
seems to be intermediate between those displayed by 7b and AMI-1. In fact, 
half of its structure is docked in the SAM methionine site, similar to AMI-1, 
and the other half occupies the same SAM adenine binding region that is also 
ort
even though it shows a stretched conformation, while AMI-1 was found
d in a bended shape. In fact, similar to AMI-1, half of 7b structure is buried 
into a hydrophobic pocket delimited by Trp262, His261, and Tyr116 side 
chains. However, the second half of 7b is located in the SAM adenine binding 
pocket, while the second half of AMI-1 is placed into the SAM methionine 
site. 
On the other hand, 1b is a DSP 
eractions with AMI-1
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filled by one of 7b’s two substituted naphthyl groups (Figure 5.1 and Figure 
5.4). 
   
Figu ndin onform s of und to Rm tic sit M 
c r lored carbon at and ello s); 
B ( ored rbon a  Th A re within from t
c un port n cornfl r blu  the s f clarit en at not 
d e
a  de tives r s c o boxyl grou as 
a ri ts to e pr stab g re t inte s. In p lar, 
o M lfon grou cts  Ar (guani ide c nd 
T  (am ic N le 1 nd t cond  main  His26
NH. On the other hand, 1  7 oxy roups,  shar me 
interactions with AMI-1 sulfonic group (H-bonds with Arg22 and His261 for 
1 , respectively, Table 1), establish new nteractio ith both
important Ile12-His13-His16-Thr49 pocket, as well as to the lack of any 




 7b in tA cataly e. A) SA




w colored car on ato
) 7b green col
e
 ca ms e Rmt idues  4.0 Å he docked 
ompo ds are r ed i owe e. For ake o y, hydrog oms are 
isplay d 
 
In ll three riva  eeith ulfoni r car ic acid ps act 
ncho ng poin  th otein e lishin levan raction articu
ne A I-1 su ic p intera  with g22 dinic s hain) a
hr49 id H) (Tab ) a he se  with  chain 1 amidic 
b and b carb lic g  while ing so
b and 7b  i ns w  Tyr116 
and Met96 (7b) or Leu52 and Tyr126 (1b). 
A deeper analysis of the above described binding modes could help explain 
the observed activity trend. The lower activity of 1b in respect to those 
observed for 7b and AMI-1 could be due to its minor interaction with the 
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interaction with the arginine anchoring residues Glu112 and Glu121 that seem 







Figure 5.4 Comparison between binding conformations of AMI-1 (magenta), 7b (green) 
and 1b (orange) into RmtA catalytic site. ). The RmtA residues within 4.0 Å from the docked 
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2.9 Glu15…OH     
3.1 Arg22…SO32-   2.7 Arg22…CO2- 
2.9 His261…SO32- 3.2 His261…CO2-   
  3.2 Tyr116…CO2-   
3.3 Met114…NH     
2.8 Glu112…NH 3.6 Glu112…OH   
  2.8 Glu121  NH   
2.7 Thr49 NH…SO32-     
  2.9 Asp68…OH 2.8 Asp68…NH 
  2.7 Met96-NH…CO2- 2.8 Met96-NH…OH 
    2.3 Glu97…OH 
    3.3 Leu52-NH…CO2- 
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Conclusion 
 
We started by stating the rationale by which 7,7’-carbonylbis-(azanediyl) 
bis(4-hydroxynaphthalene-2-sulfonic acid) (AMI-1), a selective PRMT 
inhibitor with a bisanionic structure that is related to compounds known to 
generate pleiotropic interactions with many proteins, should be further 
optimized before exploring additional nding pockets. On the basis of these 
observations, we have synthesized two series of analogue structurally related 
to the AMI-1 and characterized by the substitution of the sulfonic groups with 
the bioisosteric carboxylic groups, the replacement of the ureidic function with 
a bisamidic moiety, the intro taining basic moiety or the 
positional isomerization of the aminohydroxynaphthoic moiety as well as the 
substitution o ssessed their 
biological activity against a panel of arginine methyltransferases (fungal 
RmtA, hPRMT1, hCARM1, hPRMT3, hPRMT6), as well as against SET7/9 
and G9a lysine methyltransferase, using histone and nonhistone proteins as 
substrates. All the data obtained allowed us to understand a preliminary 
structure–activity relationships. 
 Substitution of the AMI-1 sulfonic group with the carboxylic isoster gave 
compound 1b, which maintained a fairly good activity. Moreover, derivatives 
resulting from the formal shift of the ureidic function from the C-7 to the C-6 
position of the naphthalene ring (compounds 7, 8, and 9) were more potent 
than their positional isomers. The biscarboxylic acid 7b, an isomer of 1b, 
showed the highest inhibitory efficacy in vitro and was able to prevent 
arginine methylation of cellular proteins in whole-cell assays, with activities 
comparable or even better than AMI-1. As regard to the indole moiety, the 2-
substituted showed a general decree of activity compared to the naphthalene 
counterpart due to an intramolecular hydrogen bond. This problem was solved 
bi
duction of a N-con
f the naphthol structure with an indolic one. We a
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shifting the carboxylic moiety from 2 to 3 position; compound 39b showed an 
inhibitor power similar to 7b.  
All naphthalene derivatives evaluated were found to be selective for 
arginine methyltransferases, and practically inactive against the lysine 
methyltransferase SET7/9, whereas AMI-1, due to the pleiotropic nature of 
the interactions established by the sulfonic groups, inhibits all the enzymes 
tested, albeit with different potencies, including a minor inhibition of the 
HKMT SET7/9. Differently, indole derivatives showed a general selective 
inhibition of PRMT-3 and HKMT SET7/9 among other PRMTs and HKMTs. 
This decrease in selectivity, probably due to the analogy between indole and 
SAM, may be overtaken by further fictionalization.  
Finally we identified, for the first time, CARM-1 selective activator. 
Compound 33a and 35a were the most powerful CARM-1 activator using non 
histone substrate PABP-1, and compound 31a showed a dose dependent 
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7.1 Naphthalene and indole derivatives 
All chemicals were purchased from Aldrich Chimica (Milan, Italy) or from 
Alfa Aesar GmbH (Karlsruhe, Germany) and were of the highest purity. All 
solvents were reagent grade and, when necessary, were purified and dried by 
standard methods. All reactions requiring anhydrous conditions were 
conducted under a positive atmosphere of nitrogen in oven-dried glassware. 
Standard syringe techniques were used for anhydrous addition of liquids. All 
microwave reactions were conducted using a CEM Corporation (Cologno al 
Serio (BG), Italy) Discover LabMate system using the standard 10 mL 
reaction vessel. Reactions were routinely monitored by TLC performed on 
aluminum-backed silica gel plates (Merck DC, Alufolien Kieselgel 60 F254) 
wi
involved the use of a rotary evaporator operating at a reduced pressure of ~10 
Torr. Organic solutions were dried over anhydrous sodium sulfate. 
Ch
er Avance 300 spectrometer; chemical shifts are reported in δ (ppm) units 
relative to the internal reference tetramethylsilane (Me Si). Mass spectra were 
rec
th spots visualized by UV light (λ = 254, 365 nm) or using a KMnO4 
alkaline solution. Concentration of solutions after reactions and extractions 
romatographic separations were performed on silica gel (Silica gel 60, 
0.063-0.200 mm; Merck DC) or on alumina (aluminium oxide 90, active, 
neutral, 0.063-0.200 mm; Merck DC) columns. Melting points were 
determined on a Gallenkamp melting point apparatus in open capillary tubes 
and are uncorrected. Infrared (IR) spectra (KBr) were recorded on a Shimadzu 
FTIR-8000 instrument. 1H NMR spectra were recorded at 300 MHz on a 
Bruk
4
orded on a Finnigan LCQ DECA TermoQuest (San Jose, CA, USA) mass 
spectrometer using an electrospray ion source (ESI-MS). Combustion analysis 
on target compounds were performed by our Analytical Laboratory at the 
University of Salerno. All compounds showed ≥98% purity. When the 
elemental analysis is not included, crude compounds were used in the next 
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ical studies were dried in high vacuum over P2O5 for 20 h at 
temperatures ranging from 25 to 110 °C, depending on the sample melting 
point. 
Preparation of ethyl 7-amino-4-hydroxy-2-naphthoate (13a) 
 
 
The mixture (3.00 g, 12.97 mmol) of ethyl 7-amino-4-hydroxy-2-naphthoate 
12a and ethyl 5-amino-4-hydroxy-2-naphthoate 12b, obtained as previously 
described,53 was dissolved in 150 mL of methanol and a solution of cobalt(II) 
nd then left at room temperature for additional 3 h. The black solid 
was filtered off and the solution was concentrated under reduced pressure. 
Sa
 





acetate tetrahydrate (4.00 g, 16.06 mmol) in 20 mL of AcOH/AcONa pH 5  
buffer was added dropwise in 30 min. The resulting slurry was heated to 50 °C 
for 3 h a
turated aqueous NaHCO3 solution (150 mL) was added to the resulting oil 
and the mixture was extracted with ethyl acetate (3 × 75 mL). The organic 
phase was dried over anhydrous sodium sulfate and concentrated under 
vacuum to give 12a as a white solid (0.96 g, 33%); mp 245.5-246.5 °C (dec); 
1H NMR (CDCl3) δ 10.57 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.92 (d, J = 1.2 
Hz, 1H), 7.18 (d, J = 1.2 Hz, 1H), 7.02– 6.96 (m, 2H), 5.50 (br s, 2H), 4.40 (q, 
J = 7.3 Hz, 2H), 1.41 (t, J = 7.3 Hz, 3H); MS (ESI) m/z (%): 232 (M+H)+. 
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Preparation of diethyl 7,7′-carbonylbis(azanediyl)bis(4-hydroxy-2-
naphthoate) (1a)  
 
Diphenylcarbonate (0.463 g, 2.16 mmol) and 4-dimethylaminopyridine (0.053 
g, 0.43 mmol) were added to a solution of 12a (1.0 g, 4.32 mmol) in 
chlorobenzene (20 mL) and the mixture was refluxed for 72 h. The solvent 
was evaporated under reduced pressure, and the dark brown solid obtained 
was washed twice with petroleum benzene. The solid was taken up with 100 
mL of ethyl acetate and washed with 3N HCl solution (3 × 70 mL). The 
organic phase was then washed with brine, dried and evaporated. The crude 
residue was purified by column chromatography on silica gel (gradient, 
dichloromethane/methanol, 98:2 to 90:10) to afford pure 1a as a white solid 
(0.633 g, 60%); mp 266.2-266.8 °C (dec); 1H NMR (DMSO-d6) δ 10.43 (s, 
2H), 9.11 (s, 2H), 8.16 (s, 2H), 8.10 (d, J = 8 Hz, 2H), 7.94 (s, 2H), 8.33 (d, J 
= 8 Hz, 2H), 7.25 (s, 2H), 6.45 (q, J = 7 Hz, 4H), 1.36 (t, J = 7 Hz, 6H); MS 
(ESI) m/z (%): 489 (M+H)+; Anal. calcd for C27H24N2O7: C 66.39, H 4.95, N 
General Procedure for the Preparation of Acids 1b, 2b, 3b, 4b and 6b.63 
Example: Preparation of 7,7′-carbonylbis(azanediyl)bis(4-hydroxy-2-
naphthoic acid) (1b)  
5.73, found: C 66.52, H 4.94, N 5.72. 
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The ester 1a (0.3 g, 0.61 mmol) was dissolved in a mixture of THF (4 mL) and 
pyridine (1.22 mmol, 98 µL). Aqueous 1 N sodium hydroxide (12 mL) was 
added dropwise and the mixture was stirred at room temperature until starting 
material ppeared (silica TLC, AcOEt/A OH 99/1 After  THF 
by ans nitrog 2N H  solution (10 mL) was added and the white 
pre ate as collec  b  filt on (0 8%); p >290 °C; 1H NMR 
(DMSO-d6  δ 10.37 (s, 2H), 9.09 (s,2H), 8.13-8.10 (m ), 7.  7.67 
(dd, J1 = 9Hz, J2 = 1 Hz, 2H), 7.25 (d, J = 1 Hz, 2H); S (ES  433 





3-yl)ethyl)ureido)-4-hydroxy-2-naphthoic (4b), and 5-(3-(7-carboxy-5-
hydroxynaphthalen-2-yl)ureido)-1H-indole-2-carboxylic (6b) were obtained 
from the corresponding esters 2a, 3a, 4a, and 6a, respectively, following the 
same procedure. 
2b
disa c ). removing
me
cipit
 of en flow, Cl
 w ted y rati .260 g, 9 m
) , 4H 93 (s, 2H),
 M I) m/ (%):z 
l. calcd for 
04, H 3, N 6.47. 
e acids 7-(3-(7-carboxy-5-hydroxynaphthalen-2-ylamino)-3-oxopropan- 
amido)-4-hy
 : 
white solid (yield 96%); mp >290 °C; 1H NMR (DMSO-d6) δ 10.50 (s, 2H), 
10.45 (s, 2H), 8.33 (s, 2H), 8.14 (d, J = 9 Hz, 2H), 7.93 (s, 2H), 7.73 (d, J = 9 
Hz, 2H), 7.29 (s, 2H), 3.64 (s, 2H); MS (ESI) m/z (%): 475 (M+H)+; Anal. 
calcd for C25H18N2O8: C 63.29, H 3.82, N 5.90, found: C 63.38, H 3.82, N 
5.89. 
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3b:   
white solid (yield 90%); mp >290 °C; 1H NMR (D2O + NaOD) δ 7.92 (d, J = 9 
Hz, 2H), 7.55 (d, J = 9 Hz, 2H), 7.27 (s, 2H), 7.12-7.07 (m, 4H), 2.55 (s, 4H); 
MS (ESI) m/z (%): 489 (M+H)+. Anal. calcd for C26H20N2O8: C 63.93, H 4.13, 
N 5.74, found: C 64.03, H 3.75, N 5.73. 
b: 4  
 white solid (yield 98%); mp > 290 °C; 1H NMR 1H NMR (DMSO-d6) δ 11.77 
(s, 1H), 10.83 (s, 1H), 10.25 (s, 1H), 8.75 (s, 1H), 8.00 (d, J = 7 Hz,1H), 7.98 
(s, 1H), 7.81 (s, 1H), 7.57 (d, J = 8 Hz, 1H), 7.53 (dd, J1 = 9 Hz, J2 =2 Hz, 1H), 
7.33 (d, J = 8 Hz, 1H), 7.17 (d, J = 2 Hz, 1H), 7.15 (d, J = 1 Hz, 1H), 7.08-
7.03 (m, 1H), 6.99-6.94 (m, 1H) 6.24 (t, J = 12 Hz, 1H), 3.45-3.49 (m, 2H), 
2.87 (t, J = 14 Hz, 2H); MS (ESI) m/z (%): 390 (M+H)+; Anal. calcd for 












white solid (yield 70%); mp >290 °C; 1H NMR (DMSO-d6) δ 11.62 (s, 1H), 
10.31 (s, 1H), 8.91 (s, 1H), 8.67 (s, 1H), 8.08-8.03 (m, 2H), 7.88-7.85 (m, 2H), 
7.63 (d, J = 8 Hz, 1H), 7.37 (d, J = 8Hz, 1H), 7.26 (s, 1H), 7.21 (s, 1H), 7.02 
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(s, 1H); MS (ESI) m/z (%): 406 (M+H)+; Anal. calcd for C25H23N3O6: C 65.07, 
H 5.02, N 9.11, found: C 65.19, H 5.01, N 9.10. 
Preparation of 7,7′-carbonylbis(azanediyl)bis(4-hydroxy-2-naphthamide) 
(1c) 
 
A mixture of compound 1a (0.3 g, 0.61 mmol) and ammonium hydroxide 30% 
w/w (20 ml) was stirred at room temperature for 12 h. The solution was then 
acidified to pH 5 with 3N HCl and the light brown solid thus obtained was 
recovered by filtration to obtain pure 1c (0.157 g, 60%); mp >290 °C; 1H 
NMR (DMSO-d6) δ 10.23 (s, 2H), 9.13 (s, 2H), 8.15, (s, 2H), 8.07 (d, J = 9 
Hz, 2H), 7.98 (s, 2H), 7.81 (s, 2H), 7.54 (d, J = 9 Hz, 2H), 7.31 (s, 2H), 7.18 
(s, 2H); MS (ESI) m/z (%): 431 (M+H)+. Anal. calcd for C23H18N4O5: C 64.18, 
H 4.22, N 13.02, found: C 64.29, H 4.21, N 13.00. 
Preparation of ethyl 7-(3-ethoxy-3-oxopropanamido)-4-hydroxy-2-
naphthoate (15) 
 
Intermediate 12a (1.0 g, 4.32 mmol) was suspended in 6.5 mL of diethyl 
malonate into a 10 mL microwave vessel and the mixture was irradiated for 30 
min at 300 W keeping temperature below 100 °C (air flow cooling). Ethyl 
acetate (100 mL) was added and the solution was washed with 6N HCl (3 × 70 
mL). The organic phase was dried, evaporated under reduced pressure, and the 
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crude residue was purified by co tography on silica gel (gradient, 
dichloromethane/methanol, 99:1 to 95:5) to give a light yellow solid (1.34 g, 




9 (s, 1H), 8.10 (d, J = 9 Hz, 1H), 7.92 (s, 1H), 7.64 (d, J1 = 9 Hz, 1H), 7.27 
(s, 1H), 4.32 (q, J = 7 Hz, 2H), 4.12 (q, J = 7 Hz, 2H), 3.51 (s, 2H), 1.34 (t, J = 
7 Hz, 3H), 1.20 (t, J = 7 Hz, 3H); MS (ESI) m/z (%): 346 (M+H)+. 
Preparation of ethyl 7-(3-(7-(ethoxycarbonyl)-5-hydroxynaphthalen-2-
ylamino)-3-oxopropanamido)-4-hydroxy-2-naphthoate (2a) 
 
Compound 12a (0.740 g, 3.19 mmol) was added to a solution of derivative 13 
(1.00 g, 2.90 mmol) in toluene (10 mL) and 1-methyl-2-pyrrolidinone (1 mL) 
into a 10 mL microwave vessel, and the resulting mixture was irradiated (3 × 
30 min) at 300 W keeping temperature below 120 °C (air flow cooling). After 
solvent removal under reduced pressure, the resulting oil was taken up with 
ethyl acetate (150 mL), washed with 1N HCl (3 × 60 mL), dried, evaporated 
under vacuum. The crude residue was purified by column chromatography on 
silica gel (gradient, dichloromethane/methanol, 99:1 to 90:10) to give a white 
solid (0.770 g, 50%); mp 282.2-282.7 °C; 1H NMR (DMSO-d6) δ 10.50 (s, 
2H), 10.47 (s, 2H), 8.34 (s, 2H), 8.11 (d, J = 9 Hz, 2H), 7.92 (s, 2H), 7.70(dd, 
J1 = 9 Hz, J2 =1 Hz, 2H), 7.27 (s, 2H), 4.32 (q, J = 7 Hz, 4H), 3.61 (s, 2H), 
1.33 (t, J = 7 Hz, 6H); MS (ESI) m/z (%): 531 (M+H)+; Anal. calcd for 
C29H26N2O8: C 65.65, H 4.94, N 5.28, found: C 65.76, H 4.93, N 5.27. 
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Preparation of ethyl 7-(4-(7-(ethoxycarbonyl)-5-hydroxynaphthalen-2-
ylamino)-4-oxobutanamido)-4-hydroxy-2-naphthoate (3a) 
 
A solution of 12a (1.0 g, 4.32 mmol) in acetone (6 mL) was cooled to -15 °C 
and an acetone solution (12 mL) of succinil dichloride (0.401 g, 2.59 mmol) 
was added dropwise in 30 min. The resulting solution was stirred for 12 h at 
room temperature, then aqueous NaHCO  solution (6 m3 L) was added and the 
mi
pressure. The solid thus obtained was purified by 
flash chromatography on silica gel (gradient, dichloromethane/methanol, 99:1 
to 90:10) to give a white solid (0.470 g, 40%); mp >290 °C. 1H NMR (DMSO-
d6)  10.50 (s, 2H), 10.37 (s, 2H), 8.33 (s, 2H), 8.07 (d, J = 9 Hz, 2H), 7.87 (s, 
2H), 7.68 (d, J = 9 Hz, 2H), 7.31 (s, 2H), 4.31 (q, J = 7 Hz, 4H), 2.83 (s, 2H), 
1.33 (t, J = 7 Hz, 6H). MS (ESI) m/z (%): 545 (M+H)+. Anal. calcd for 





xture concentrated under vacuum. The residual oil was taken up with 
aqueous NaHCO3 (100 mL) and extracted with ethyl acetate (3 × 60 mL). The 
combined organic phases were washed with 2N HCl (3 × 60 mL), dried and 
evaporated under reduced 
 δ
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Preparation of ethyl 4-hydroxy-7-(2,2,2-trichloroacetamido)-2-naphthoate 
(16) 
 
Triethylamine (0.674 g, 6.67 mmol) was added to a solution of compound 13a 
(1.0 g, 4.32 mmol) in dry dichlorom ane (100 mL) under nitrogen flow. 
After 30 min trichloroacetylchloride (1.212 g, 6.67 mmol) was added dropwise 
in 10 min under nitrogen flow s stirred at room temperature 
for 4 h. The solution was then washed with saturated aqueous NaHCO3 
solution (3 × 40 centrated under 
duced pressure, and purified by column chromatography on silica gel 
ethane/methanol, 99:1 to 90:10) to give a light yellow 
solid (1.34 g, 83%); mp 232.0-232.7 °C; 1H NMR (DMSO-d6) δ 11.06 (s, 1H), 
10.56 (s, 1H), 8.29 (s, 1H), 8.16 (d, J = 9 Hz, 1H), 7.99 (s, 1H), 7.80 (d, J = 9 
Hz, 1H), 7.33 (s, 1H), 4.34 (q, J = 7 Hz, 2H), 1.34 (t, J = 7 Hz, 3H); MS (ESI) 
(+) m/z (%): 376 (M+H, 100); 378 (M+H+2, 96); 380 (M+H+4, 36); 382 
(M+H+6, 4). 




 and the reaction wa
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Sodium carbonate (1.40 g, 13.25 mmol) and tryptamine (0.467 g, 2.91 mmol) 
were added to a solution of derivative 16 (1.0 g , 2.65 mmol) in dry DMF (10 
he resulting mixture was heated at 150 °C for 1 h, the 
solvent was removed under reduced pressure, and ethyl acetate (150 mL) was 
added to the residual oil. The solution was then washed with 2N HCl (3 × 
50mL) and saturated aqueous NaHCO3 solution (3 × 50mL), dried, evaporated 
under reduced pressure, and purified by column chromatography on silica gel 
(gradient, dichloromethane/methanol, 99:1 to 90:10) to give a white solid 
(0.696 g, 63%); mp 214.7-215.5 °C; 1H NMR (DMSO-d6) δ 10.82 (s, 1H), 
10.39 (brs, 1H), 8.79 (d, J = 4 Hz, 1H), 8.03-7.99 (m, 2H), 7.84 (s, 1H), 7.59-
7.51 (m, 2H), 7.34 (d, J = 9 Hz, 1H), 7.19-7.18, (m, 2H), 7.06-7.03 (m, 1H), 
6.97-6.95 (m, 1H), 6.29 (t, J = 6 Hz, 1H), 4.31 (q, J = 7 Hz, 2H), 4.43-4.41 (m, 
2H), 2.91 (t, J = 7 Hz, 2H), 1.33 (t, J = 7 Hz, 3H); MS (ESI) m/z (%): 418 
(M+H)+; Anal. calcd for C24H23N3O4: C 69.05, H 5.55, N 10.07, found C 
69.14, H 5.54, N 10.06. 
Ethyl 7-(3-(2-(dimethylamino)propyl)ureido)-4-hydroxy-2-naphthoate (5a) 
and ethyl 5-(3-(7-(ethoxycarbonyl)-5-hydroxynaphthalen-2-yl)ureido)-1H-
indole-2-carboxylate (6a) were obtained following the same procedure starting 
from 16 and N1,N1-dimethylpropane-1,3-diamine or ethyl 5-amino-1H-indole-
2-carboxylate, respectively, as nucleophile. 
5a:
mL) in a sealed tube. T
  
white solid (yield 63%); mp 161-163 °C; 1H NMR (DMSO-d6) δ 10.36 (s, 
1H), 8.76 (s, 1H), 8.03-8.00 (m, 2H), 7.85 (s, 1H), 7.55 (dd, J1 = 9 Hz, J2 =1 
Hz, 1H), 7.19 (s, 1H), 6.34 (t, J = 9 Hz, 1H), 4.33 (q, J =7 Hz, 2H), 3.17-3.11 
(m, 2H), 2.36-2.31 (m, 2H), 2.20 (s, 6H), 1.63-1.58 (m, 2H), 1.34 (t, J = 7 Hz, 
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3H); MS (ESI) m/z (%): 360 (M+H)+; Anal. calcd for C19H25N3O4: C 63.49, H 
7.01, N 11.69, found: C 63.57, H 7.00, N 11.67. 
 6a: 
white solid (yield 50%); mp 210.8-211.7 °C; 1H NMR (DMSO-d6) δ 11.74 (s, 
1H), 10.39 (s, 1H) 8.98 (s, 1H), 8.75 (s, 1H), 8.17 (s, 1H), 8.08 (d, J = 9Hz, 
1H), 7.94-7.88 (m, 2H), 7.64 (d, J = 8 Hz, 1H), 7.39 (d, J = 8 Hz, 1H) 7.27 (d, 
J = 9 Hz, 1H), 7.23 (s, 1H), 7.07 (s, 1H), 4.35 (m, 4H), 1.38-1.32 (m, 6H); MS 
(ESI) m/z (%): 462 (M+H)+; Anal. calcd for C25H23N3O6: C 65.07, H 5.02, N 
9.11, found: C 65.17, H 5.01, N 9.10. 
Preparation of (E)-3-(methoxycarbonyl)-4-(4-nitrophenyl)but-3-enoic acid 
 
Carboxyphosphorane 1050 (13.0 g, 35.2 mmol) was suspended in dry benzene 
(150 mL) and 4-nitrobenzaldehyde (5.74 g, 38.0 mmol) was then added. The 
resulting mixture was stirred at room temperature for 48 h and then extracted 
with saturated NaHCO3 solution (3 × 70 mL). The aqueous phase was washed 
with ethyl ether, acidified with concentrated HCl and the white solid formed 
was recollected by filtration (8.60 g, 92%) and directly used in the following 
step without further purification; mp 1H NMR (DMSO-d6) δ 8.30 (d, J = 9 Hz, 
2H), 7.86 (s, 1H), 7.69 (d, J = 9 Hz, 2H), 3.78 (s, 3H), 3.43 (s, 2H); MS (ESI) 
m/z (%): 266 (M+H)+. 
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Preparation of methyl 4-acetoxy-6-nitro-2-naphthoate (17) 
 
A round-bottomed flask containing a magnetic stirring bar and fitted with a 
flux condenser was charged with a mixture of (E)-3-(methoxycarbonyl)-4-
(4-nitrophenyl)but-3-enoic acid (5.0 g, 18.85 mmol), Ac2O (35 mL) and 
subjected to MW irradiation 
re
NaOAc (2.30g, 28.27 mmol). The flask was 
(power 300 W) for 5 min keeping temperature below 120 °C (air flow 
cooling). The reaction mixture was filtered and the solvent evaporated to give 
a pure yellow solid (5.17 g, 95%); mp 167-168 °C; 1H NMR (CDCl3) δ 8.89 
(d, J = 2 Hz, 1H), 8.62 (s, 1H), 8.38 (dd, J1 = 9 Hz, J2 = 2 Hz, 1H), 8.17 (d, J = 
9 Hz, 1H), 8.05 (s, 1H), 4.05 (s, 3H), 2.59 (s, 3H); MS (ESI) m/z (%): 290 
(M+H)+. 
Preparation of methyl 4-acetoxy-6-amino-2-naphthoate (18) 
 
Pd/C (5 wt % palladium on activated carbon, 0.1 eq) was added to a solution 
of 17 (3.0 g, 10.37 mmol) in ethanol (100 mL), and the reaction was stirred 
under 1 atm of H2 (balloon) for 2h. The reaction mixture was filtered and, after 
lvent evaporation, a light yellow solid was recollected (2.66 g, 99%); mp 
1H NMR (DMSO-d6) δ 8.28 (s, 1H), 7.86 (d, J = 9 Hz, 1H), 7.54 
(s, 1H), 7.06 (d, J = 9 Hz, 1H), 6.79 (s, 1H), 6.04 (s, 2H), 3.87 (s, 3H), 2.42 (s, 
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Preparation of dimethyl 6,6′-carbonylbis(azanediyl)bis(4-hydroxy-2-
naphthoate) (7a) 
 
, 2H), 3.85 (s, 6H); MS (ESI) m/z (%): 
461 (M+H)+; Anal. calcd for C25H20N2O7: C 65.21, H 4.38, N 6.08, found: C 
General Procedure for the Preparation of acids 7b, 8b and 9b.  
The acids 6,6′-carbonylbis(azanediyl)bis(4-hydroxy-2-naphthoic acid) (7b), 6-
(3-(6-carboxy-8-hydroxynaphthalen-2-ylamino)-3-oxopropanamido)-4-
hydroxy-2-naphthoic acid (8b), and 6-(3-(2-(1H-indol-3-yl)ethyl)ureido)-4-
Diphenylcarbonate (0.411 g, 1.92 mmol) and 4-dimethylaminopyridine (0.046 
g, 0.38 mmol) were added to a solution of 18 (1.0 g, 3.85 mmol) in 
chlorobenzene (20 mL) and the mixture was refluxed for 72 h. The solvent 
was evaporated under reduced pressure, and the dark brown solid obtained 
was washed twice with petroleum benzene. The crude product obtained was 
dissolved in ethanol (50 mL) and K2CO3 (0.585 g, 4.23 mmol) was added. The 
mixture was heated at 70 °C for 2 h, then evaporated, taken up with 100 mL of 
ethyl acetate and washed with 3N HCl solution (3 × 70 mL). The organic 
phases were collected, washed with brine, dried and evaporated. The crude 
residue was purified by column chromatography on silica gel (gradient, 
dichloromethane/methanol, 98:2 to 90:10) to afford pure 7a as a white solid 
(0.443 g, 50%); mp 276.6-277.6 °C; 1H NMR (DMSO-d6) δ 10.39 (s, 2H), 
9.13 (s, 2H), 8.42 (d, J = 2 Hz, 2H), 8.00 (s, 2H), 7.95 (d, J = 9 Hz, 2H), 7.56 
(dd, J1 = 9 Hz, J2 = 2 Hz, 2H), 7.33 (s
65.29, H 4.37, N 6.07. 
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hydroxy-2-naphthoic acid (9b) were obtained from the corresponding esters 
7a, 8a, and 9a, respectively, following the same general procedure above 
described for 1b, 2b, 3b, 4b and 6b. 
7b:  
 white solid (yield 90%); mp>290 °C; 1H NMR (DMSO-d6) δ 10.33 (s, 2H), 
9.13 (s, 2H), 8.44 (d, J = 2 Hz, 2H), 8.00 (s, 2H), 7.96 (d, J = 9 Hz, 2H), 7.59 
(dd, J1 = 9 Hz, J2 = 2 Hz, 2H), 7.35 (s, 2H); MS (ESI) m/z (%): 433 (M+H)+; 
Anal. calcd for C23H16N2O7: C 63.89, H 3.73, N 6.48, found: C 63.95, H 3.73, 
N 6.47. 
8b:  
white solid (yield 85%); mp >290 °C; 1H NMR (CD3OD) δ 8.54 (d, J = 2 Hz, 
2H), 8.09 (s, 2H), 7.91 (d, J = 9 Hz, 2H), 7.76 (dd, J1 = 9 Hz, J2 = 2 Hz, 2H), 
7.39 (s, 2H), 3.51 (s, 2H); MS (ESI) m/z (%): 475 (M+H)+; Anal. calcd for 
C25H18N2O8: C 63.29, H 3.82, N 5.90, found: C 63.38, H 3.81, N 5.89. 
 
9b:  
white solid (yield 98%); mp >290 °C;1H NMR (DMSO-d6) δ 10.86 (s, 1H), 
10.21 (s, 1H) 8.87 (s, 1H), 8.29 (d, J = 2 Hz, 1H), 7.94 (s, 1H), 7.86 (d, J = 9 
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Hz, 1H), 7.61 (d, J = 8 Hz), 7.53 (dd, J1 = 9 Hz, J2 = 2 Hz, 1H), 7.37 (d, J = 8 
Hz, 1H), 7.30 (d, J = 1 Hz, 1H), 7.21 (d, J =1 Hz, 1H), 7.09-7.05 (m, 1H), 
7.00-6.95 (m, 1H), 6.24 (t, J = 7 Hz, 1H), 3.47-3.43 (m, 2H), 2.91 (t, J = 7 
Hz); MS (ESI) m/z (%): 390 (M+H)+; Anal. calcd for C22H19N3O4: C 67.86, H 
, N 10.79, found: C 67.96, H 4.91, N 10.78. 4.92
Preparation of methyl 4-acetoxy-6-(3-ethoxy-3-oxopropanamido)-2-
naphthoate (19) 
 
Title compound was obtained starting from 18 (1.0 g, 3.85 mmol) following 
ame procedure above described for the pr aration of 13, to yield a white 
1
the s ep
solid (1.30 g, 90%); mp. 170.5-171.9 °C; H NMR (DMSO-d6) δ 10.66 (s, 
1H), 8.52 (s, 1H), 8.32 (s, 1H), 8.20 (d, J = 9 Hz, 1H), 7.80-7.76 (m, 2H), 4.16 
(q, J = 7 Hz, 2H), 3.93 (s, 3H), 3.56 (s, 2H), 2.47 (s, 3H), 1.22 (t, J = 7 Hz, 
3H); MS (ESI) m/z (%): 374 (M+H)+. 
Preparation of methyl 4-hydroxy-6-(3-(6-(methoxycarbonyl)-8-
hydroxynaphthalen-2-ylamino)-3-oxopropanamido)-2-naphthoate (8a) 
 
Compound 16 (0.762 g, 2.94mmol) was added to a solution of compound 18 
(1,00 g, 2.68 mmol) in toluene (10 mL) and 1-methyl-2-pyrrolidinone (1 mL) 
and the mixture was irradiated (3 × 30 min) at 300 W, keeping temperature 
below 120 °C (air flow cooling). After solvent removal under reduced 
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pressure, the residual oil was taken up with ethyl acetate (150 mL), washed 
with 1N HCl (3 × 60 mL), dried, and evaporated under vacuum. The crude 
residue thus obtained was dissolved in ethanol (50 mL) and K CO  (0.407 g, 
L of ethyl acetate and washed with 3N HCl 
solution (3 × 70 mL). The organic phase was washed with brine, dried and 
evaporated. The mixture was then purified by column chromatography on 
silica gel (gradient, dichloromethane/methanol, 99:1 to 90:10) to give a white 
solid (0.673 g, 50%); mp. 287.8-288.8 °C. 1H NMR (DMSO- 6) δ 10.51 (s, 
2 3
2.94 mmol) was added. The mixture was heated at 70 °C for 2h, then 
evaporated, taken up with 100 m
d
2H), 10.44 (s, 2H), 8.55 (d, J = 2 Hz, 2H), 8.01 (s, 2H), 7.98 (d, J = 9 Hz, 2H), 
7.73 (dd, J1 = 9 Hz, J2 = 2 Hz, 2H), 7.32 (s, 2H), 3.86 (s, 6H), 3.60 (s, 2H); 
MS (ESI) m/z (%): 503 (M+H)+; Anal. calcd for C27H22N2O8: C 64.54, H 4.41, 
N 5.58, found: C 64.61, H 4.40, N 5.57. 
Preparation of methyl 4-acetoxy-6-(2,2,2-trichloroacetamido)-2-
naphthoate (20a) and methyl 4-hydroxy-6-(2,2,2-trichloroacetamido)-2-
naphthoate (20b) 
 
Title compounds were obtained as a mixture starting from the intermediate 
198 (1.0 g, 3.85 mmol) following the same procedure above described for the 
preparation of 14, to yield a crude white solid (1.14 g, 82%) that was directly 
used in the following step. For characterization purposes, analytical samples of 
20a and 20b were obtained by column chromatography on silica gel (gradient, 
dichloromethane/methanol, 99:1 to 95:5); 20a: mp 162-163 °C; 1H NMR 
(DMSO-d6) δ 11.25 (s, 1H), 8.56 (s, 1H), 8.32 (s, 1H), 8.27 (d, J = 9 Hz, 1H), 
8.03 (d, J = 9 Hz, 1H), 7.80 (s, 1H), 3.93 (s, 3H), 2.51 (s, 3H); 20b: mp 225-
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226 °C; 1H NMR (DMSO-d6) δ 11.13 (s, 1H), 10.63 (s, 1H), 8.55 (s, 1H), 
8.07-8.05 (m, 2H), 7.85 (dd, J1 = 9 Hz, J2 = 2 Hz), 7.39 (s, 1H), 3.89 (s, 3H); 
MS (ESI) m/z (%): 362 + 404 (M+H)+. 
Preparation of methyl 6-(3-(2-(1H-indol-3-yl)ethyl)ureido)-4-hydroxy-2-
naphthoate (9a) 
 
Compound 9a was prepared starting from the crude mixture of 20a and 20b 
(1.0 g , 2.77 mmol) following the same procedure above described for the 
preparation of 4a, to yield a white solid (0.704 g, 63%); mp 218.8-219.8 °C; 
1H NMR (DMSO-d6) δ 10.83 (s, 1H), 10.26 (s, 1H), 8.87 (s, 1H), 8.26 (d, J = 
2 Hz, 1H), 7.95 (s, 1H), 7.86 (d, J = 9 Hz, 1H), 7.57 (d, J = 8 Hz, 1H), 7.51 
(dd, J1 = 9 Hz, J2 = 2 Hz, 1H), 7.33 (d, J = 8 Hz, 1H), 7.27 (s, 1H), 7.17 (d, J = 
2 Hz, 1H), 7.06-7.03 (m, 1H), 6.97-6.93 (m, 1H), 6.22 (t, J = 6 Hz, 1H), 3.84 
(s, 3H), 3.44-3.40 (m, 2H), 2.87 (t, J = 7 Hz); MS (ESI) m/z (%): 404 (M+H)+; 
Anal. calcd for C23H21N3O4: C 68.47, H 5.25, N 10.42, found: C 68.58, H 
5.24, N 10.41. 
Synthesis of ethyl 5-amino-1H-indole-2-carboxylate (26): 
 
 To a solution of ethyl 5-nitro-1H-indole-2-carboxylate (500 mg; 2.24 mmol) 
 ethanol (250 ml), 5% palladium on activated carbon (237 mg, 0.112 mmol) 
was added. The reaction was stirred under H2 (1 atm) for 12h at room 
temperature. The colorless solution was filtrated and the solvent evaporated 
in
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under vacuum yielding 452 mg of a white solid (99%). 1H NMR (DMSO-d6) δ 
11.39 (s, 1H); 7.16 (d, J = 9 Hz, 1H); 6.84 (s, 1H); 6.71 - 6.68 (m, 3H); 4.65 (s, 
2H); 4.30 (q, J = 7 Hz, 2H); 1.32 (t, J = 7 Hz, 3H). ESI m/z: 205 [M + H]+. 
Mp: 113 – 115 °C 
Synthesis of methyl 5-amino-1H-indole-3-carboxylate (37): 
 
 Compound 10 was prepared following the same procedure of 26 starting from 
methyl 5-nitro-1H-indole-3-carboxylate (500 mg; 2.27 mmol), yielding 427 
mg of a white solid (99%).1H NMR (DMSO-d6) δ 11.49 (s, 1H), 7.82 (s, 1H), 
7.17 (d, J= 2Hz, 1H), 7.13 (d, J= 9Hz, 1H), 6.55 (dd, J1= 9Hz, J2= 2Hz, 1H), 
4.74 (brs, 2H), 3.75 (s, 3H). ESI m/z =  191 [M+H]+. Mp: 144-146 °C 
Synthesis of diethyl 5,5'-(carbonylbis(azanediyl))bis(1H-indole-2-
carboxylate) (21a):  
 
To a solution of 26 (437 mg; 2.14 mmol) in dry DCM (80 ml), triethylamine 
as added (446 µl, 3.21 mmol). A solution of trifosgene (254 mg; 0.856 
ry DCM (10 ml) was then added dropwise over 10 min. The 
tion mixture was stirred for additional 30 min and then 1 (437 mg, 2.14 
mol) and triethylamine (446 µl, 3.21 mmol) in dry DCM (10 ml) was added 
dropwise. The reaction mixture was stirred at room temperature under N2 for 
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AcOEt (180 ml) and then washed with 1N HCl (3 x 60 ml), with NaHCO3 
saturated solution (3 x 60 ml), brine and anhydrified over Na2SO4.  After 
solvent evaporation, the resulting solid was recrystallized from acetonitrile 
yielding 650 mg of a white solid (70%). 1H NMR (DMSO-d6) δ 11.71 (s, 2H); 
8.48 (s, 2H,); 7.83 (s, 2H); 7.35 (d, J = 9 Hz, 2H); 7.22 (dd, J1 = 9 Hz, J2 = 2 
Hz, 2H); 7.06 (s, 2H); 4.31 (q, J = 7 Hz, 4H); 1.32 (t, J = 7 Hz, 6H). ESI m/z: 
+ 435 [M + H] M.p.: 292.3 - 293 °C. 
Synthesis of 5,5'-(carbonylbis(azanediyl))bis(1H-indole-2-carboxylic acid) 
(21b): 
 
 To a solution of 21a (55 mg: 0.126 mmol) in THF/H2O (10 ml), NaOH (101 
mg; 2.53 mmol) and pyridine (20.µL; 0.253 mmol) were added and the 
resulting mixture was stirred at room temperature for 12h. The solvent was 
then evaporated and the resulting oil taken up with H2O (20 ml). The water 
phase was washed with DCM (3 x 10 ml), acidified to pH 2 with HCl and 
extracted with AcOEt (3 x 10 ml). The organic phase was collected, washed 
DMSO-d6) δ 11.53 (s, 2H); 8.54 (s, 2H); 7.80 (s, 2H); 7.32 
(d, J = 9 Hz, 2H); 7.21 (d, J = 9 Hz, 2H); 6.97 (s, 2H). ESI m/z: 379 [M + H]+ 
M.p. : > 300 °C. 
 
 
with brine and anhydrified over Na2SO4, evaporated and purified by column 
chromatography (SiO2, AcOEt/ACOH 99:1), yielding 39 mg of a white solid 
(82%). 1H NMR (
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Synthesis of dimethyl 5,5'-(carbonylbis(azanediyl))bis(1H-indole-3-
carboxylate) (38a):  
 
Compound 38a was prepared following the same procedure of 21a starting 
from 37. Crystallization from ethanol yield  800 mg of a light brown solid 
(87%). 1H NMR (DMSO-d6) δ 11.81 (brs, 2H),  8.53 (s, 2H), 8.07 - 8.00 (m, 
4H),  7.40 - 7.36 (m, 4H), 3.80 (s, 6H). ESI m/z = 407 [M+H+] M.p: 250 °C d. 
Synthesis of 5,5'-(carbonylbis(azanediyl))bis(1H-indole-3-carboxylic acid) 
(38b):  
 
Compound 38b was prepared following the same procedure of 21b starting 
from 38a (0.80 g; 0.197 mmol), yielding 23 mg a brown solid (30%).1H NMR 
(DMSO-d6) δ 11.57 (s, 2H), 8.47 (s, 2H), 8.13 (s, 2H), 7.92 (d, J=2 Hz, 2H), 
7.34 (d, J= 8 Hz, 2H), 7.27 (d, J= 8 Hz, 2H).  ESI m/z =  379 [M+H] +, 401  
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Synthesis of diethyl 5,5'-(succinylbis(azanediyl))bis(1H-indole-2-
carboxylate) (22a): 
 
 brine, anhydrified over Na2SO4, and 
(SiO2, gradient, DCM/AcOEt, 8:2 to 1:1) yielding 400 mg of a white solid 
(70%).1H NMR (DMSO-d6) δ 11.74 (s, 2H); 9.86 (s, 2H); 8.01 (s, 2H); 7.41 – 
7.34 (m, 4H); 7.05 (s, 2H); 4.31 (q, J = 7 Hz, 4H); 2.64 (s, 4H); 1.31 (t, J = 7 
Hz, 6H). ESI m/z: 491 [M + H]+ M.p: > 300°C 
 A solution of 26 (390 mg; 1.91 mmol) and triethylamine (531 µl; 3.28 mmol) 
in acetone (8 ml) was cooled at -78 °C, succinyl chloride (231 µl; 2.10 mmol) 
was added dropwise and the resulting mixture was stirred for 2h. Solvent was 
then evaporated and the resulting oil taken up with water (50 ml). Aqueous 
phase was extracted with AcOEt (3 x 15 ml); the organic phase were collected, 
washed with 3N HCl (3 x 15 ml),
evaporated under vacuum. The solid was purified by column chromatography 
Synthesis of 5,5'-(succinylbis(azanediyl))bis(1H-indole-2-carboxylic acid) 
(22b):  
 
Compound 22b was prepared following the same procedure of 21b starting 
from 22a (0.040 g; 0.0815 mmol), yielding 35 mg of a white solid (98%).1H 
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NMR (DMSO-d6) δ 11.62 (s, 2H); 9.86 (s, 2H); 8.00 (s, 2H); 7.43 – 732 (m, 
4H); 6.99 (s, 2H); 2.64 (s, 4H). ESI m/z: 435 [M + H]+M.p: 272 - 273°C 
Synthesis of dimethyl 5,5'-(succinylbis(azanediyl))bis(1H-indole-3-
carboxylate) (40a): 
 
 Compound 40a was prepared following the same procedure of 22a starting 
from 37 (800 mg; 4,20 mmol). Crystallization from acetonitrile yield  456 mg 
of white solid (47 %). 1H NMR (DMSO-d ) δ 11.84 (s, 2H), 9.94 (s, 2H), 8.26 
(s, 2H), 8.01 (s, 2H), 7.47 (d, J= 9 Hz, 2H), 7.37 (d, J= 9 Hz, 2H), 3.78 (s, 6H), 
2.67 (s, 4H).ESI m/z =  463 [M+H] + M.p: 269 - 271 °C  
6
Synthesis of ethyl 5-(3-ethoxy-3-oxopropanamido)-1H-indole-2-
carboxylate (27): 
 
 Compound  26 (610 mg; 2.99 mmol) and diethylmalonate (6 ml) were placed 
in a microwave vessel, and irradiated for 20 min at 300W keeping temperature 
below 100 °C using air flow. The reaction mixture was then diluted with 
AcOEt (100 ml), washed with 1N HCl (3 x 30ml), brine, anhydrified over 
Na2SO4, and evaporated under vacuum. The resulting oil was purified by 
column chromatography (SiO2, gradient, DCM/AcOEt, 9:1 to 8:2) yielding 
570 mg of a brown solid (60%).1H NMR (DMSO-d6) δ 11.81 (s, 1H); 10.06 (s, 
1H); 7.99 (s, 1H); 7.38 (d, J = 9 Hz, 1H); 7.30 (d, J = 9 Hz, 1H); 7.09 (s, 1H); 
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4.31 (q, J =7 Hz, 2H); 4.11 (q, J = 7 Hz, 2H); 3.43 (s, 2H); 1.29 (t, J = 7, 3H); 
1.19 (t, J = 7, 3H). ESI m/z: 319 [M + H]+M.p.: 156 - 158 °C. 
Synthesis of methyl 5-(3-ethoxy-3-oxopropanamido)-1H-indole-3-
carboxylate (41): 
 
 Compound 41 was prepared following the same procedure of 27 starting from 
37 (431 mg; 2.27 mmol). Purification by column chromatography (SiO2, 
gradient, DCM/MeOH, 95:5 to 90:10) yield a 400 mg of a brown solid (58%). 
1H NMR (DMSO-d6) δ 11.87 (s, 1H) 10.12 (s, 1H), 8.22 (s, 1H), 8.04 (d, J= 2 
Hz, 1H), 7.45 (d, J= 9 Hz, 1H), 7.40 (d, J= 9 Hz, 1H), 4.11 (q, J= 7 Hz, 2H), 
3.79 (s, 3H), 3.45 (s, 2H), 1.21 (t, J= 7 Hz, 3H).ESI m/z =  305 [M+H] + M.p: 
171 - 173 °C 
Synthesis of diethyl 5,5'-(malonylbis(azanediyl))bis(1H-indole-2-
carboxylate) (23a): 
 
icrowave vessel compound 26 (143 mg; 0.703 mmol) and 27 (146 mg; 
0.457 mmol) were solubilized in toluene (5 ml) and N-methyl-pyrrolidinone 
below 120 
rganic 
 In a m
(0.5 ml) and irradiated (3 x 40 min) at 300W keeping temperature 
°C. Solvent was evaporated, the resulting oil was taken up with HCl 4N (100 
ml), the aqueous phase was extracted with AcOEt (3 x 50 ml). The o
phase was collected, washed with brine, anhydrified over Na2SO4, and 
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evaporated under vacuum. The resulting oil was purified by column 
chromatography (SiO2, gradient, DCM/MeOH, 99:1 to 90:10) yielding 156 mg 
of a brown solid (65%).1H NMR (DMSO-d6) δ 11.81 (s, 2H); 10.10 (s, 2H); 
8.04 (s, 2H); 7.42 – 7.35 (m, 4H); 7.10 (s, 2H); 4.31 (q, J = 7 Hz, 4H); 3.47 (s, 
2H); 1.33 (t, J = 7 Hz, 6H). ESI m/z: 477 [M + H]+ M.p.: 259 - 260 °C 




 Compound 39a was prepared following the same procedure of 23a starting 
from 41 (400 mg; 1.32 mmol) and 37 (426 mg; 2.24 mmol). Crystallization 
from ethanol yield 291 mg of a white solid (49%).1H NMR (DMSO-d6) δ 
7 (s, 2H), 10.15 (s, 2H), 8.29 (d, J= 2 Hz, 2H), 8.06 s, 2H), 7.50 (dd, J1= 
9 Hz, J2= 2 Hz, 2H), 7.43 (d, J= 9 Hz, 2H), 3.80 (s, 6H), 3.50 (s, 2H). ESI m/z 
3 :
11.9  (
=  449 [M+H] + M.p: 283 - 285 °C. 
Synthesis of 5,5'-(malonylbis(azanediyl))bis(1H-indole-2-carboxylic acid) 
(2 b)  
 
 Compound 23b was prepared following the same procedure of 21b starting 
from 23a (148 mg; 0.310 mmol), yielding 100 mg of a light brown solid 
(77%).1H NMR (DMSO-d6) δ 11.71 (s, 2H); 10.09 (s, 2H); 8.05 (s, 2H); 7.41 
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– 7.34 (m, 4H); 7.07 (d, J = 1.5 Hz, 2H); 3.49 (s, 2H). ESI m/z: 421 [M + H]+ 
M.p.: 227.5 – 228.2 °C 
 












HOOC COOH  
 Compound 39b was prepared following the same procedure of 21b starting 
from 39a (140 mg; 0.32 mmol), yielding 30 mg of a light brown solid 
(25%).1H NMR (DMSO-d6) δ 11.77 (s, 2H), 10.11 (s, 2H), 8.29 (s, 2H), 7.97 
(d, J= 2 Hz, 2H), 7.51 (d, J= 9 Hz,  2H), 7.41 (d, J= 9 Hz, 2H), 3.50 (s, 2H). 
ESI m/z =  421 [M+H]+ M.p: 211 - 213°C d. 
Synthesis of ethyl 5-(2,2,2-trichloroacetamido)-1H-indole-2-carboxylate 
(28): 
 
 To a solution of 26 (436 mg; 2.13 mmol) and triethylamine (447 μL; 3.20 
mmol) in dry DCM (10 ml), trichloroacetylchloride (357 μL; 3.20 mmol) was 
evaporation, the resulting solid was purified by column chromatography (SiO2, 
added dropwise. After 30 min at room temperature, solvent was evaporated 
and the resulting oil taken up with 100 ml of AcOEt. The organic phase was 
washed with NaHCO3 saturated solution (3 x 30ml), 10% citric acid water 
solution (3 x 30ml), brine and anhydrified over Na2SO4. After solvent 
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gradient, DCM/MeOH, 99:1 to 90:10) yielding 545 mg of yellow solid (73%). 
1H NMR (CDCl3) δ 8.89 (s, 1H); 8.38 (s, 1H), 8.02 (s, 1H); 7.45 (d, J = 9 Hz, 
1H); 7.39 (d, J = 9 Hz, 1H); 7.22 (s, 1H); 4.42 (q, J = 7 Hz, 2H); 1.43 (t, J = 7 
Hz, 3H).  ESI m/z: 349 (100%) [M + H]+; 351 (70%) [M + 2H]+; 353 (30%) 
[M + 4H]+ Mp: 196.9 – 197.8 °C 
Synthesis of methyl 5-(2,2,2-trichloroacetamido)-1H-indole-3-carboxylate 
(42):  
 
Compound 42 was prepared following the same procedure of 28 starting from 
37 (427 mg; 2.25 mmol), yielding 698 mg of a white solid (92%). 1H NMR 
 [M+2+H+], 339 (30%) [M+4+H] +. M.p: 202 - 204 °C 
Synthesis of ethyl 5-(3-(2-(1H-indol-3-yl)ethyl)ureido)-1H-indole-2-
carboxylate (30a):  
(DMSO-d6) δ  12.00 (s, 1H), 10.79 (s, 1H), 8.31 (s, 1H), 8.11 (s, 1H), 7.49 (d, 
J= 9 Hz, 1H), 7.44 (d, J= 9 Hz, 1H), 3.81 (s, 3H). ESI m/z =  335 (100%) 
[M+H+], 337 (70%)
 
In a sealed vessel 28 (224 mg; 0.69 mmol), triptamine (176 mg; 1.10 mmol) 
and Na2CO3 (364 mg; 3.43 mmol) were suspended in dry DMF (15 ml). The 
reaction mixture was heated to 150 °C for 1h. The solvent was then 
evaporated, the resulting oil was diluted in NH4Cl saturated solution (100 ml) 
and extracted with AcOEt (3 x 50 ml). The organic phase was collected, 
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washed with brine, anhydrified over Na2SO4 and evaporated under vacuum. 
The resulting brown solid was purified by column chromatography (SiO2, 
AcOEt/DCM, 1:1) yielding 236 mg of white solid (88%). 1H NMR (DMSO-
d ) δ 11.64 (s, 1H); 10.81 (s, 1H); 8.33 (s, 1H); 7.75 (s, 1H); 7.56 (d, J = 9, 
); 6.03 (t, J = 6 Hz, 1H); 4.30 (q, J = 7 Hz, 2H); 3.45 - 3.39 
(m, 2H); 2.84 (t, J = 7 Hz, 2H); 1.32 (t, J = 7 Hz, 3H). ESI m/z: 391 [M + H]+ 
Mp: 232.2 - 232.7 °C 
Synthesis of methyl 5-(3-(2-(1H-indol-3-yl)ethyl)ureido)-1H-indole-3-
6
1H); 7.34 (d, J = 9 Hz, 1H); 7.31 (d, J = 9 Hz, 1H); 7.16 (d, J = 2 Hz, 1H); 
7.05 – 6.96 (m, 4H
carboxylate (43a):  
 
Compound 43a was prepared following the same procedure of 30a starting 
from 42 (400 mg; 1.18 mmol), yielding 335 mg of a white solid (75%). 1H 
NMR (DMSO-d6) δ 11.76 (s, 1H), 10.83 (s, 1H), 8.44 (s, 1H), 8.00 - 7.97 (m, 
2H), 7.60 (d, J= 8 Hz, 1H),  7.36 (d, J= 8 Hz, 1H), 7.34-7.32 (m, 2H), 7.18 (d, 
J= 2 Hz, 1H), 7.11-7.06 (m, 1H), 7.00-6.96 (m, 1H), 6.03 (t, J= 6 Hz, 1H),  
3.79 (s, 3H), 3.44-3.40 (m, 2H), 2.87 (t, J= 7 Hz, 2H). ESI m/z =  377 [M+H] + 
Synthesis of 5-(3-(2-(1H-indol-3-yl)ethyl)ureido)-1H-indole-2-carboxylic 
acid (30b):  
M.p: 225 - 227°C d. 
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Compound 30b was prepared following the same procedure of 20b starting 
from 30a (124 mg; 0.32 mmol), yielding 72 mg of a light brown solid (62%). 
1H NMR (DMSO-d6) δ 11.44 (s, 1H); 10.81 (s, 1H); 8.27 (s, 1H); 7.71 (s, 1H); 
7.56 (d, J = 9 Hz, 1H); 7.33 (d, J = 9 Hz, 1H); 7.26 (d, J = 9 H, 1H); 7.16 (d, J 
= 2 Hz, 1H); 7.12 – 7. 03 (m, 2H, scambiabile con D O); 6.99 – 6.94  (m, 1H); 
 m/z: 363 [M + 
H]+ M.p.: 249 - 250 °C 
Synthesis of 5-(3-(2-(1H-indol-3-yl)ethyl)ureido)-1H-indole-3-carboxylic 
acid (43b): 
2
6.91 (s, 1H); 6.03 (t, J = 6 Hz, 1H); 2.84 (t, J = 7 Hz, 2H) ESI
 
 Compound 43b was prepared following the same procedure of 21b starting 
from 43a (140 mg; 0.37 mmol), yielding 50 mg of a white solid (36%).1H 
) δ
7.18 (s, 1H), 7.09-7.04 (m, 1H), 7.00-6.95 (m, 1H) 5.98 (t,J= 6 Hz, 1H), 4.60 - 
4.56 (m, 2H), 2.87 (t, J= 7 Hz, 2H). ESI m/z =  363 [M+H+] 385 [M+Na+] 
M.p: 223-224 °C d. 
NMR (DMSO-d6  11.61 (s, 1H), 10.82 (s, 1H), 8.39 (s, 1H), 8.00 (s, 1H); 
7.89 (s, 1H), 7.58 (d, J= 8 Hz, 1H),  7.34 (d, J= 8 Hz, 1H), 7.28 - 7.23 (m, 2H), 
Synthesis of ethyl 5-(2-((tert-butoxycarbonyl)amino)acetamido)-1H-
indole-2-carboxylate (29a): 
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A solution of HOBt (347 mg; 2.57 mmol), HBtU (925 mg; 2.57 mmol), Boc-
Gly-OH (375 mg, 2.14 mmol) and DIEA (918 µl; 5.14 mmol) in 9 ml of dry 
THF/DMF (7/2) was added to a solution of 26 (500 mg; 2.14 mmol) in THF (3 
ml). After 12h, the solvent was evaporated and the resulting oil was taken up 
with AcOEt (100 ml). The organic phase was washed with NaHCO3 saturated 
solution (3 x 30 ml), 5% citric acid water solution (3 x 30ml), brine and 
anhydrified over Na2SO4. After solvent evaporation, the resulting solid was 
purified by column chromatography (SiO , AcOEt/HEX 7:3) yielding 629 mg 
6
, 2H); 7.08 (d, J = 2 Hz, 1H); 6.99 (t, J = 6 Hz 1H); 4.31 
(q, J = 7 Hz, 2H); 3.70 (d, J = 6 Hz, 2H); 1.38 (s, 9H); 1.32 (t, J = 7 Hz, 3H). 
ESI m/z: 362 [M + H]+ M.p: 193.0 – 193.9 °C 
Synthesis of methyl 5-(2-((tert-butoxycarbonyl)amino)acetamido)-1H-
2
of white solid (81%). 1H NMR (DMSO-d ) δ 11.78 (s, 1H); 9.78 (s, 1H); 7.98 
(s, 1H); 7.38 – 7.33 (m
indole-3-carboxylate (44a): 
 
 Compound 16 was prepared following the same procedure of 29a starting 
from 37 (442 mg; 1.90 mmol), yielding 680 mg of a white solid (70%).1H 
NMR (DMSO-d6) δ 11.85 (s, 1H), 9.85 (s, 1H), 8.22 (s, 1H), 8.03 (d, J= 2 Hz, 
1H), 7.46 (dd, J1= 9 Hz, J2= 2 Hz, 1H), 7.39 (d, J= 9 Hz, 1H), 7.01 (t, J= 6 Hz, 
1H), 3.79 (s, 3H), 3.73 (d, J= 6 Hz, 2H), 1.41 (s, 9H). ESI m/z = 348 [M+H]+ 
M.p: 214.7 – 216.0 °C 
ynthesis of 2-((2-(ethoxycarbonyl)-1H-indol-5-yl)amino)-2-
oxoethanaminium 2,2,2-trifluoroacetate (29b):  
S
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To a suspension of 29a (500 mg, 1.38 mmol) in DCM (4 ml), TFA (4 ml) was 
added and the resulting solution was stirred at room temperature for 30 min. 
The solution was than evaporated yielding 520 mg of a white solid (99.9%). 
1H NMR (DMSO-d6) δ 11.88 (s, 1H); 10.30 (s, 1H); 8.08 (brs, 2H); 7.99 (s, 
1H); 7.43 (d, J = 9 Hz, 1H); 7.34 (d, J = 9 Hz, 1H); 7.14 (s, 1H); 4.33 (q, J = 7 
Hz, 2H); 3.77 (s, 2H); 1.34 (t, J = 7 Hz, 3H).ESI m/z: 262 [M + H]+ M.p: 
225.4 – 226.3 °C 
Synthesis of 2-((3-(methoxycarbonyl)-1H-indol-5-yl)amino)-2-
oxoethanaminium 2,2,2-trifluoroacetate (44b): 
 
 Compound 44b was prepared following the same procedure of 29b starting 
 the synthesis of compounds 31a-36a and 45a-50a: 
o a solution of the proper arylisocianate (1.20 mol eq) in dry THF (8 ml), a 
dry THF solution (20 ml) of indole derivative (1 mol eq) and triethylamine (3 
ol eq) was added dropwise. The resulting mixture was stirred at room for 12 
. The solid formed was recovered by filtration, washed with water (3 x 20 ml) 
and diethyl ether (3 x 20 ml), yielding pure compound 31a-36a. 
from 44a (500 mg; 1.38 mmol), yielding 520 mg of a white solid (99.9%).1H 
NMR (DMSO-d6) δ 11.93 (s, 1H), 10.31 (s, 1H), 8.26 (s, 1H), 8.06 (d, J= 2 
Hz, 1H), 7.96 - 7.70 (m, 2H), 7.47 - 7.41(m, 2H),  3.79 (s, 3H), 3.75 - 3.70 (m, 
2H). ESI m/z = 248 [M+H]+ M.p: 229.0 – 230.0 °C  
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 white solid (70%).  1H NMR (DMSO-d6) δ 11.84 (s, 1H); 9.99 (s, 1H); 9.74 
(s, 1H); 8.18 (d, J = 9 Hz, 2H); 8.02 (s, 1H); 7.67 (d, J = 9 Hz, 2H); 7.43 – 
7.36 (m, 2H); 7.12 (s, 1H); 6.85- 6.84 (m, 1H); 4.35 (q, J = 7 Hz, 2H); 3.99 (d, 
J = 5 Hz, 2H); 1.35 (t, J = 7 Hz, 3H). ESI m/z: 426 [M + H]+ M.p: 288.9 – 
289.7 °C 
ethyl 5-(2-(3-phenylureido)acetamido)-1H-indole-2-carboxylate (32a)  
 
white solid (75%).  1H NMR (DMSO-d6) δ 11.81 (s, 1H); 9.94(s, 1H);  8.82 (s, 
, 1H) 6.43 (t, J=5Hz, 1H); 4.36 (q, J=7 Hz, 2H); 3.94 (d, J=5Hz, 2H); 
1.35 (t, J = 7 Hz, 3H). ESI m/z: 381 [M + H] +, 403 [M + Na] + M.p:263,3-
265,4 d 
ethyl 5-(2-(3-(p-tolyl)ureido)acetamido)-1H-indole-2-carboxylate (33a)  
1H); 7.99 (s, 1H); 7.41-7.38 (m, 4H); 7.25-7.20(m, 2H); 7.10 (s, 1H); 6.92-
6.87 (m
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white solid (84%) 1H NMR (DMSO-d6) δ  11.80 (s, 1H); 9.92(s, 1H); 8.70 (s, 
1H); 7.99 (s, 1H); 7.40-7.33 (m, 2H); 7.28 (d, J=8Hz, 2H); 7.09 (s, 1H); 7.02 
(d, J= 8Hz, 2H);  6.37 (t, J= 5Hz, 1H); 4.36 (q, J=7Hz, 2H); 3.93 (d, J=5Hz, 
ethyl 5-(2-(3-(4-methoxyphenyl)ureido)acetamido)-1H-indole-2-
carboxylate (34a) 
2H); 2.21 (s,3H); 1.35(t, J = 7 Hz, 3H). ESI m/z: 395 [M + H] + 417 [M + Na]+ 
M.p:271,9-273,3 d 
 
 white solid (77%) 1H NMR (DMSO-d6) δ  11.80 (s, 1H); 9.91(s, 1H); 8.61 (s, 
1H); 7.99 (s, 1H); 7.40-7.37 (m, 2H); 7.30 (d, J=8Hz, 2H); 7.10 (s, 1H); 6.81 
(d, J=8Hz, 2H); 6.31 (t, J= 5Hz, 1H); 4.36 (q, J=7Hz, 2H); 3.93 (d, J=5Hz, 
ethyl 5-(2-(3-(4-cyanophenyl)ureido)acetamido)-1H-indole-2-carboxylate 
(35a)  
2H); 3.69 (s,3H); 1.35(t, J = 7 Hz, 3H). ESI m/z: 411[M + H] + M.p: 257,9-
260,3 d 
 
white solid (72%) 1H NMR (DMSO-d6) δ 11.80 (s, 1H); 9.95(s, 1H);  9.38 (s, 
1H); 7.99 (s, 1H); 7.67 (d, J=8Hz, 2H); 6.58 (d, J=8Hz, 2H); 7.38-7.37 (m, 
2H) 7.10 (s,1H) 6.64 (t, J= 5Hz, 1H); 4.36 (q, J=7Hz, 2H); 3.97 (d, J=5Hz, 
2H); 1.35(t, J = 7 Hz, 3H). ESI m/z: 406 [M + H] + M.p:280-282 d 
  ‐ 119 ‐       





                                                                              Chapter 7: Experimental data 
ethyl 5-(2-(3-(4-(dimethylamino)phenyl)ureido)acetamido)-1H-indole-2-
carboxylate (36a)  
 
white solid (71%) 1H NMR (DMSO-d6) δ 11.70 (s, 1H); 9.90 (s, 1H);  8.45 (s, 
1H); 7.99 (s, 1H); 7.43-7.33 (m, 2H);  7.22 (d, J= 9Hz, 2H); 7.09 (s, 1H);  6.66 
(d, J= 9Hz, 2H); 6.29 (t, J= 5Hz, 1H); 4.32 (q, J= 7Hz, 2H);  3.90 (d, J=5Hz, 




white solid (69%) 1H NMR (DMSO-d6) δ 11.87 (s, 1H), 10.04 (s, 1H), 9.66 (s, 
1H), 8.27 (s, 1H), 8.16 (d, J= 9 Hz, 2H), 8.06 (d, J= 2 Hz, 1H), 7.65 (d, J= 9 
Hz, 2H), 7.47 - 7.44 (m, 2H), 6.73 (t, J= 4 Hz, 1H), 3.99 (d, J= 4 Hz, 2H), 3.79 
(s, 3H). ESI m/z = 412 [M+H]+ M.p: 289 – 290 °C d 
methyl 5-(2-(3-phenylureido)acetamido)-1H-indole-3-carboxylate (46a)  
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white solid (63%) 1H NMR (DMSO-d6) δ   11.87 (s, 1H), 9.99 (s, 1H), 8.82 (s, 
1H), 8.25 (s, 1H), 8.04 (s, 1H), 7.47-7.39 (m, 4H), 7.25-7.20 (m, 2H), 6.90 (t, 
J=7 Hz, 1H), 6.42 (t, J=5Hz, 1H), 3.95 (d, J= 5Hz, 2H), 3.79 (s, 3H). ESI m/z 
= 367 [M+H] +, 389 [M+Na] + M.p: 260-262 °C d 
methyl 5-(2-(3-(p-tolyl)ureido)acetamido)-1H-indole-3-carboxylate (47a)  
 
white solid (83%) 1H NMR (DMSO-d6) δ 11.86 (s, 1H), 9.98 (s, 1H), 8.70 (s, 
1H), 8.25 (s, 1H), 8.03 (d, J= 2Hz, 1H), 7.45-7.38 (m, 2H), 7.29 (d, J= 9Hz, 
2H), 7.03 (d, J= 9Hz, 2H), 6.38 (t, J= 5Hz, 1H), 3.94 (d, J= 5Hz, 2H), 3.79 (s, 
3H), 2.21 (s, 3H). ESI m/z= 381 [M+H] +, 403 [M+Na] + M.p: 271-273 °C d 
methyl 5-(2-(3-(4-methoxyphenyl)ureido)acetamido)-1H-indole-3-
carboxylate (48a)  
 
white solid (81%) 1H NMR (DMSO-d6) δ 11.85 (s, 1H), 9.96 (s, 1H), 8.61 (s, 
1H), 8.25 (s, 1H), 8.03 (d, J= 2Hz, 1H), 7.45 (d, J= 9Hz, 1H), 7.40 (d, J= 9Hz, 
1H), 7.30 (d, J= 8Hz, 2H), 6.82 (d, J= 8Hz, 2H), 6.32 (t, J= 5Hz, 1H), 3.93 (d, 
J= 5Hz, 2H), 3.70 (s, 3H), 3.70 (s, 3H). ESI m/z =  397 [M+H] +, 419 [M+Na] 
+ M.p: 249-250 °C d 
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methyl 5-(2-(3-(4-cyanophenyl)ureido)acetamido)-1H-indole-3-
carboxylate (49a)  
 
white solid (79%) 1H NMR (DMSO-d6) δ 11.86 (s, 1H), 10.01 (s, 1H), 9.39 (s, 
1H), 8.25 (s, 1H), 8.03 (d, J= 2Hz, 1H), 7.68 (d, J= 9Hz, 2H), 7.59 (d. J= 9Hz, 
2H), 7.45 (dd, J1= 9Hz, J2= 2Hz, 1H), 7.40 (d, J= 9Hz, 1H), 6.65 (t, J= 5Hz, 
1H), 3.97 (d, J= 5Hz, 2H), 3.79 (s, 3H). ESI m/z = 392 [M+H] +, 411 [M+Na] + 
M.p: 268-271 °C d 
methyl 5-(2-(3-(4-(dimethylamino)phenyl)ureido)acetamido)-1H-indole-3-
carboxylate (50a)  
 
white solid (65%) 1H NMR (DMSO-d6) δ 11.85 (s, 1H), 9.94 (s, 1H), 8.41 (s, 
1H), 8.25 (s, 1H), 8.03 (d, J= 2Hz, 1H), 7.46 (dd, J1= 9Hz, J2= 2Hz, 1H), 7.40 
(d, J= 9Hz, 1H), 7.21 (d, J= 9Hz, 2H), 6.66 (d, J= 9Hz, 2H), 6.25 (t, J= 5Hz, 
1H), 3.92 (d, J= 5Hz, 2H), 3.79 (s, 3H), 2.80 (s, 6H). ESI m/z = 432 [M+Na] + 
M.p: 244.5-246.8 °C d 
General procedure for the synthesis of compounds 31b-36b: Compound 
31a-36a (1.00 mol eq) dissolved in a mixture 4/1 of THF/H20 (20 ml), NaOH 
(10.00 mol eq) and pyridine (0.20 mol eq) added and the resulting mixture was 
stirred at room temperature for 12h. The solvent was then evaporated and the 
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resulting oil taken up with H2O (20 ml). The water phase was washed with 
DCM (3 x 10 ml), acidified to pH 2 with concentrated HCl. The resulting solid 




white solid (90%) 1H NMR (DMSO-d6) δ 11.71 (s, 1H); 9.98 (s, 1H); 9.67(s, 
1H); 8.18 (d, J = 9 Hz, 2H); 8.00 (s, 1H); 7.67 (d, J = 9 Hz, 2H); 7.40 – 7.33 
(m, 2H); 7.06 (s, 1H); 6.74 – 6.73 (m, 1H); 4.00 (d, J = 5 Hz, 2H). ). ESI m/z = 
383 [M+H] + M.p: 283.5 – 283.9 °C  
5-(2-(3-phenylureido)acetamido)-1H-indole-2-carboxylic acid (32b) 
 
 white solid (931H NMR (DMSO-d6) δ 11.68 (s, 1H); 9.93(s, 1H); 8.84 (s, 
1H); 7.98 (s, 1H); 7.41-7.35 (m, 4H); 7.25-7.20(m, 2H); 7.04 (s, 1H); 6.92-
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5-(2-(3-(p-tolyl)ureido)acetamido)-1H-indole-2-carboxylic acid (32b)  
 
white solid (96%) 1H NMR (DMSO-d6) δ 11.80 (s, 1H); 9.92(s, 1H); 8.70 (s, 
1H); 7.99 (s, 1H); 7.40-7.33 (m, 2H); 7.28 (d, J=8Hz, 2H); 7.04-7.01 (m, 3H); 
6.37 (t, J= 5Hz, 1H); 3.93 (d, J=5Hz, 2H); 2.21 (s,3H). ESI m/z = 367 [M+H] 
5-(2-(3-(4-methoxyphenyl)ureido)acetamido)-1H-indole-2-carboxylic acid 
(33b)  














white solid (89%) 1H NMR (DMSO-d6) δ 11.67 (s, 1H); 9.89(s, 1H); 8.61 (s, 
1H); 7.98 (s, 1H); 7.38-7.35 (m, 2H); 7.30 (d, J=8Hz, 2H); 7.03 (s, 1H); 6.81 
(d, J=8Hz, 2H); 6.32 (t, J= 5Hz, 1H); 3.93 (d, J=5Hz, 2H); 3.69 (s, 3H). ESI 
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 white solid (93%) 1H NMR (DMSO-d6) δ 11.68 (s, 1H); 9.94(s, 1H);  9.39 (s, 
1H); 7.97 (s, 1H); 7.67 (d, J=8Hz, 2H); 6.58 (d, J=8Hz, 2H); 7.38-7.31 (m, 
2H) 7.04 (s,1H) 6.64 (t, J= 5Hz, 1H); 3.97 (d, J=5Hz, 2H). ESI m/z = 378 
[M+H] + M.p: 269-270 °C d 
5-(2-(3-(4-(dimethylamino)phenyl)ureido)acetamido)-1H-indole-2-
carboxylic acid (35b) 
 
 white solid (81%) 1H NMR (DMSO-d6) δ  11.69 (s, 1H); 9.95 (s, 1H);  9.15 
(s, 1H); 7.99 (s, 1H); 7.55-7.45 (m, 4H); 7.39-7.32 (m, 2H); 7.03 (s, 1H); 
6.54(s, 1H); 3.94(s, 2H); 3.07 (s, 6H). ESI m/z = 396 [M+H] + M.p: 241-243 
°C d 
Synthesis of tert-butyl 5-nitro-1H-indole-3-carboxylate: 
 
 5-nitro-1H-indole-3-carboxylic acid (500 mg; 2.42 mmol) was poured in a 
sealed vessel and dissolved with dry DMF (5 ml). TEA (1.01 ml; 7.26 mmol), 
tert-Butanol (3.40 ml; 36.30 mmol) and DCC (1.50 g; 7.26 mmol) were then 
added and the resulting mixture was heated at 120 °C for 3h. Solvent was then 
evaporated and the resulting oil was taken up with AcOEt (100 ml), washed 
with NaHCO3 (3 x 60 ml) and brine (60 ml). Organic phase was anhydrified 
over sodium sulphate, filtered, concentrated under vacuum and purified by 
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column chromatography (SiO2, DCM/AcOEt 9:1) yielding 585 mg of light 
brown solid (92%). 1H NMR (DMSO-d6) δ 9.11 (s, 1H), 8.86 (s, 1H), 8.18 
(dd, J1= 9 Hz, J2= 2 Hz, 1H), 8.01 (d, J= 2 Hz, 1H), 7.46 (d, J= 9 Hz, 1H), 1.67 
(s, 9 H).  ESI m/z = 261 [M+H] + M.p: 212-214 °C 
Synthesis of tert-butyl 5-amino-1H-indole-3-carboxylate (51): 
 
 To a solution of 31 (500 mg; 1.90 mmol) in ethanol (150 ml), 5% palladium 
on activated carbon (237 mg, 0.112 mmol) was added. The reaction was 
evaporated under vacuum yielding 420 mg of a 
white solid (95%). 1H NMR (DMSO-d6) δ 11.62 (s, 1H), 8.32 (s, 1H), 7.90 (d, 
J= 2 Hz, 1H), 7.62 (brs, 2H), 7.36 (d, J= 9 Hz, 1H), 6.90 (d, J= 9 Hz, 1H), 1.56 
(s, 9H). ESI m/z: 233 [M + H]+. Mp: 60 – 63 °C 
Synthesis of tert-butyl 5-(2-((((9H-fluoren-9-
stirred under H2 (1 atm) for 12h at room temperature. The colorless solution 
was filtrated and the solvent 
yl)methoxy)carbonyl)amino)acetamido)-1H-indole-3-carboxylate (52a): 
 
 a solution of HOBt (349 mg; 2.28 mmol), HBtU (865 mg; 2.28 mmol), Fmoc-
42 mg; 1.90 mmol) in dry 
THF (3 ml). After 12h, the solvent was evaporated and the resulting oil was 
Gly-OH (558 mg, 1.90 mmol) and DIEA (400 µl; 2.28 mmol) in 18 ml of dry 
THF/DMF (7/2) was added to a solution of 51 (4
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taken up with AcOEt (100 ml). The organic phase was washed with NaHCO3 
saturated solution (3 x 30 ml), 5% citric acid water solution (3 x 30ml), brine 
and anhydrified over Na2SO4. After solvent evaporation, the resulting solid 
was purified by column chromatography (SiO , DCM/AcOEt 7:3) yielding 
9
2
680 mg of white solid (70%). 1H NMR (DMSO-d6) δ 11.75 (s, 1H), 9.85 (s, 
1H), 8.32 (s, 1H), 7.91 - 7.7.88 (m, 3H), 7.74 (d, J= 8 Hz, 2H), 7.66 - 7.62 (m, 
1H), 7.45 - 7.31 (m, 6H), 4.32 - 4.26 (m, 3H), 3.81 (d, J= 6 Hz, 2H), 1.59 (s, 
H). ESI m/z: 534 [M + Na]+, 550 [M + K]+. Mp: 95 – 97 °C 
Synthesis of tert-butyl 5-(2-aminoacetamido)-1H-indole-3-carboxylate 
(52b):  
 
To a suspension of 52a (400 mg; 0.78 mmol) in DCM (8 ml), piperidine (2 ml) 
was added and the resulting mixture was stirred at RT for 30 min. The solvent 
was then evaporated and the resulting solid was washed with hexane (3 x 30 
ml) yielding 225 mg of a white solid (99%).1H NMR (DMSO-d6) δ 11.75 (s, 
1H), 9.85 (s, 1H), 8.35 (s, 1H), 7.90 (s, 1H), 7.38 - 7.34 (m, 2H), 7.25 - 7.16 
(m,  2H), 2.79 - 2.75  (m, 2H), 1.56 (s, 9H). ESI m/z: 312 [M + Na]+. Mp: 89 – 
91 °C 
Synthesis of di-tert-butyl 5,5'-(succinylbis(azanediyl))bis(1H-indole-3-
carboxylate) (53): 
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 To a solution of 51 (500 mg; 2.14 mmol) in acetone (10ml), TEA was added 
(598 µl; 4.28 mmol) and the reaction mixture was cooled to -78°C. Succinyl 
chloride (188 µl; 1.71 mmol) was then added dropwise and the reaction was 
slowly warmed to RT and stirred for 12h. Solvent was then evaporated and the 
resulting oil was taken up with NaHCO3 saturated solution (100ml) and 
extracted with AcOEt (3 x 30 ml). The organic phase was collected, washed 
with 10% citric acid water solution (3 x 30 ml), brine (50 ml), anhydrified 
Na]+. Mp: 223 – 225 °C d 
To a solution of the proper arylisocianate (1.20 mol eq) in dry THF (8 ml), a 
dry THF solution (20 ml) of 52b (1 mol eq) and triethylamine (3 mol eq) was 
added dropwise. The resulting mixture was stirred at room for 12 h. The solid 
formed was recovered by filtration, washed with water (3 x 20 ml) and diethyl 
over Na2SO4 and evaporated under vacuum. Purification by column 
chromatography (SiO2, DCM/AcOEt 6:4) yield 200 mg of brown solid 
(36%).1H NMR (DMSO-d6) δ 11.69 (s, 2H), 9.87 (s, 2H), 8.30 (s, 2H), 7.87 (s, 
2H), 7.41 - 7.32 (m, 4H), 2.66 (s, 4H),  1.54 (s, 18H). ESI m/z: 547 [M + H]+, 
569 [M + 
General procedure for the synthesis of compounds 55-60:  




 yellow solid (71%) 1H NMR (DMSO-d6) δ 11.76 (s, 1H), 9.98 (s, 1H), 9.65 
(s, 1H), 8.32 (s, 1H), 8.15 (d, J= 9 Hz, 2H), 7.91 (d, J= 2 Hz, 1H), 7.65 (d, J= 9 
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Hz, 2H), 7.40 - 7.37 (m, 2H), 6.72 (t, J= 5 Hz, 1H), 4.00 (d, J= 5 Hz, 2H), 1.57 
(s, 9H). ESI m/z: 476 [M + Na]+. Mp: 237-239  °C d 
tert-butyl 5-(2-(3-phenylureido)acetamido)-1H-indole-3-carboxylate (56):  
 
.white solid (65%) 1H NMR (DMSO-d6) δ 11.76 (s, 1H), 9.94 (s, 1H), 8.82 (s, 
1H), 8.32 (s, 1H), 7.91 (d, J= 2Hz, 1H), 7.42-7.37 (m, 5H), 7.25-7.20 (m, 2H), 
6.89 (t, J= 5Hz, 1H), 3.95 (d, J= 5Hz, 2H), 1.57 (s, 9H). ESI m/z: 409 [M + 




 white solid (80%) 1H NMR (DMSO-d6) δ 11.75 (s, 1H), 9.93 (s, 1H), 8.72 (s, 
1H), 8.32 (s, 1H), 7.91 (s, 1H), 7.38-7.35 (m, 2H), 7.29 (d, J= 8Hz, 2H), 7.03 
(d, J= 8Hz, 2H), 6.38 (t, J= 5Hz, 1H), 3.94 (d, J= 5Hz, 2H), 2.21 (s, 3H), 1.57 
+ +(s, 9H). ESI m/z: 423 [M + H] , 445 [M + Na] .  Mp: 242-245  °C d 
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ylate (59):  
 white solid (67%) 1H NMR (DMSO-d6) δ 11.75 (s, 1H), 9.92 (s, 1H), 8.62 (s, 
1H), 8.32 (s, 1H), 7.91 (s, 1H), 7.39-7.36 (m, 2H), 7.32 (d, J= 9Hz, 2H), 6.82 
(d, J= 9Hz, 2H), 6.33 (t, J= 5hz, 1H), 3.94 (d, J= 5Hz, 2H), 3.69 (s, 3H), 1.57 




white solid (75%) 1H NMR (DMSO-d6) δ 11.76 (s, 1H), 9.96 (s, 1H), 9.44 (s, 
1H), 8.31 (s, 1H), 7.91 (s, 1H), 7.97 (d, J= 9Hz, 2H), 7.59 (d, J= 9Hz, 2H), 





ESI m/z: 456 [M + Na] . Mp: 228-230  °C d 
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 white solid (71%) 1H NMR (DMSO-d6) δ 11.78 (s, 1H), 9.92 (s, 1H), 8.50 (s, 
1H), 8.32 (s, 1H), 7.90 (d, J= 2Hz, 1H), 7.38-7.35 (m, 2H), 7.21 (d, J= 9Hz, 
2H), 6.67 (d, J= 9Hz, 2H), 6.30-6.32 (m, 1H) 3.92 (d, J= 5Hz, 2H), 2.80 (s, 
), 
TFA (3 ml) was added. The resulting mixture was stirred at RT for 1 h. 
5,5'-(succinylbis(azanediyl))bis(1H-indole-3-carboxylic acid) (40b): 
6H), 1.57 (s, 9H). ESI m/z: 452 [M + H]+, 474 [M + Na]+.  Mp: 225-227  °C d 
General procedure for the synthesis of compounds 40b, 45b-50b: To a 
suspension of tert-butyl ester derivatives 53-60 (1.20 mol eq) in DCM (10 ml
Solvent was then evaporated yielding pure 40b,45b-60b 
 
 white solid (99%) 1H NMR (DMSO-d6) δ 11.69 (s, 2H), 9.89 (s, 2H), 8.25 (s, 
2H), 7.92 (s, 2H), 7.48 (d, J= 9 Hz, 2H); 7.33 (d, J= 9 Hz, 2H), 2.66 (s, 4H). 
ESI m/z: 435 [M + H]+ Mp: 230-232  °C d 
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 yellow solid (99%) 1H NMR (DMSO-d6) δ 11.89 (s, 1H), 11.75 (s, 1H), 10.00 
(s, 1H), 9.63 (s, 1H), 8.16 (d, J= 9Hz, 2H), 7.95 (d, J=2Hz, 1H), 7.65 (d, J= 
9Hz, 2H), 7.47 (d, J= 8 Hz, 1H), 7.39 (d, J= 8 Hz, 1H), 6.72 (t, J= 5Hz, 1H), 
3.98 (d, J= 5Hz, 2H). ESI m/z: 398 [M + H]+.  Mp: 283-285  °C d 
5-(2-(3-phenylureido)acetamido)-1H-indole-3-carboxylic acid (46b):  
 
white solid (99%) 1H NMR (DMSO-d6) δ 11.74 (s, 1H), 9.96 (s, 1H), 8.81 (s, 
1H), 8.24 (s, 1H), 7.95 (d, J= 2Hz, 1H), 7.48-7.37 (m, 4H),  7.25-7.20 (m, 2H), 
6.92-6.97 (m, 1H), 6.42 (t, J= 5Hz, 1H), 3.94 (J= 5Hz 2H). ESI m/z: 353 [M + 
H]+, 357 [M + Na]+.  Mp: 249-250  °C d 
5-(2-(3-(p-tolyl)ureido)acetamido)-1H-indole-3-carboxylic acid (47b):  
 
white solid (99%) 1H NMR (DMSO-d6) δ 11.86 (s, 1H), 9.95 (s, 1H), 8.70 (s, 
1H), 8.24 (s, 1H), 7.96 (d, J= 2Hz, 1H), 7.46 (d, J= 8Hz, 1H), 7.38 (d, J= 8Hz, 
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1H), 7.28 (d, J= 9Hz, 2H), 7.03 (d, J= 9Hz, 2H), 6.38 (t, J= 5Hz, 1H), 3.94 (d, 
J= 5Hz, 2H), 2.21 (s, 3H). ESI m/z: 367 [M + H]+, 389 [M + Na]+.  Mp: 271-




white solid (99%) 1H NMR (DMSO-d6) δ 11.74 (s, 1H), 9.95 (s, 1H), 8.61 (s, 
1H), 8.22 (s, 1H), 7.94 (d, J=2Hz, 1H), 7.45 (d, J= 8Hz, 1H), 7.36 (d, J= 8Hz, 
1H), 7.28 (d, J= 9Hz, 2H), 6.80 (d, J= 9Hz, 2H),  6.33 (t, J= 5Hz, 1H), 3.93 (d, 





white solid (99%) 1H NMR (DMSO-d6) δ 11.75 (s, 1H), 9.99 (s, 1H), 9.40 (s, 
1H), 8.23 (s, 1H), 7.95 (d, J= 2Hz, 1H),  7.68 (d, J= 9Hz, 2H), 7.58 (d, J= 9Hz, 
2H), 7.46 (d, J= 8Hz, 1H), 7.38 (d, J= 8Hz, 1H), 6.65 (brs, 1H), 3.95 (d, J= 
Hz, 2H). ESI m/z: 376 [M + H]+.  Mp: 228-230 °C d 5
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5-(2-(3-(4-(dimethylamino)phenyl)ureido)acetamido)-1H-indole-3-
carboxylic acid (50b): 
 
white solid (99%) 1H NMR (DMSO-d6) δ 11.88 (s, 1H), 10.02 (s, 1H), 9.33 (s, 
1H) 8.26 (s, 1H), 7.94 (s, 1H), 7.47
+
-7.36(m,6H),  6.67 (s, 1H,), 3.93 (s, 2H), 
2.37 (s, 6H).  ESI m/z: 396 [M + H] .  Mp: 201-204 °C d 
ndole derivatives 
General Experimental 
Tetrahydrofuran, hexanes, diethyl ether, and ethyl acetate (Fisher ACS grade) 
were used as received. Column chromatography was performed using EM 
Science 230-400-mesh silica gel.  1H NMR, 13C NMR spectra were recorded 
 quint (pentet), m (multiplet), and 
br (broad).  Coupling constants, J, are reported in Hertz.   
spectroscopy was performed by the Scripps Research Institute Mass 
Spectrometer Center. Electron impact (EI) was obtained using methane as the 
carrier gas. Analytical thin-layer chromatography was performed on Merck 
silica gel plates with QF-254 indicator.  Visualization was accomplished with 
anisaldehyde or KMnO4.   
7.2 Oxi
on 400 MHz, 1H (100 MHz, 13C), 500 MHz, 1H (126 MHz, 13C) spectrometers.  
Spectra were referenced to residual chloroform (δ 7.26 ppm, 1H; δ 77.00 ppm, 
13C).  Chemical shifts are reported in ppm (δ); multiplicities are indicated by s 
(singlet), d (doublet), t (triplet), q (quartet),
Mass 
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High performance liquid chromatography (HPLC) was performed on Hatachi 
detectors (λ = 254 nm) using Daicel Chiralpak IC, OD-H, AD-H, and OJ-H 
columns.  Retention times (tR) and peak areas for HPLC were obtained from 
reporting integrators.  Oxindole starting materials were prepared according to 
published procedures. 



















Di-tert-butyl  azodicarboxylate (22 mg, 0.095 mmol, 1.2 equiv) was added to a 
solution of oxindole (27 mg, 0.079 mmol, 1 equiv.) and dimeric catalyst (2.9 
mg, 0 0.05 equiv.) in toluene (0.8 mL) at -70 C. The resulting solution was 
stirred at -70 0C for up to 48 h. The reaction mixture was then quenched with a 
ueous layer was 
separated and extracted with ethylacetate (3x). The combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by flash column chromatography (hexanes/ethyl acetate; 
4:1) to afford the 3-aryl-3-amine-2-oxindole derivative. 
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 white solid, yield 93 %; 1H NMR (500 MHz, CDCl3) δ 8.25 (d, J = 7.3 Hz, 
1H), 7.80 (d, J = 8.0 Hz, 1H), 7.58 – 7.51 (m, 2H), 7.38 – 7.32 (m, 1H), 7.32 – 
7.21 (m, 4H), 6.32 (s, 1H), 1.60 (s, 9H), 1.29 (s, 9H), 1.19 (s, 9H); 13C NMR 
(125 MHz, CDCl3) δ 174.22, 154.90, 153.21, 149.23, 138.89, 133.07, 129.80, 
128.92, 128.36, 126.59, 124.54, 114.89, 84.33, 83.19, 81.02, 72.61, 28.19, 
HRMS (m/z): [M+H]+ calcd for C29H37N3O7+ 540.270, found 540.272. 
Enantiomeric excess: 98%, determined by HPLC (Chiralpak AD-H, hexane/i-
PrOH = 90: 10, flow rate 1.00 mL/min, λ = 220 nm, rt): tR (major) = 17.5 min, 
tR (minor) = 12.2 min. 
28.10, 27.80.  









6.88 (dd, J = 8.9 and 2.7 Hz, 1H), 6.27 (s, 1H), 3.88 (s, 3H), 1.59 (s, 3H), 1.29 
(s, 3H), 1.22 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 174.12, 156.93, 154.78, 
153.28, 149.29, 133.29, 132.32, 130.57, 129.68, 128.88, 128.36, 115.82, 
114.12, 112.68, 84.12, 83.21, 80.96, 72.89, 55.86, 28.20, 28.08, 27.85. HRMS 
(m/z): [M+H]+ calcd for C30H39N3O8+ 570.281, found 570.2804. Enantiomeric 
white solid, yield 96%; H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 2.4 Hz, 
1H), 7.71  (d, J = 8.9 Hz, 1H), 7.54 (d, J = 3.7 Hz, 2H), 7.30-7.28 (m, 3H
excess: 96%, determined by HPLC (Chiralpak OD-H, hexane/i-PrOH = 99: 1, 
flow rate 1.00 mL/min, λ = 220 nm, rt): tR (major) = 20.4 min, tR (minor) = 
13.0 min. 
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white solid, yield 71%; 1H NMR (500 MHz, CDCl ) δ 8.31  (d, J = 7.2 Hz, 
J
J = 8.1 Hz, 1H), 6.37 (s, 1H), 2.38 (s, 3H), 1.68 (s, 9H), 1.38 (s, 9H), 
1.27 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 174.2, 154.8, 153.1, 149.1, 138.8, 
138.7, 129.9, 129.6, 129.5, 128.9, 128.7, 126.4, 124.4, 114.7, 84.1, 83.0, 80.8, 
72.3, 28.1, 28.0, 27.7, 21.0. HRMS (m/z): [M+H]+ calcd for C30H39N3O7+ 
554.2861, found 554.2862. Enantiomeric excess: 96%, determined by HPLC 
3
1H), 7.86  (d,  = 7.9 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.43-7.36 (m, 2H), 
7.18 (d, 
(Chiralpak AD-H, hexane/i-PrOH = 90: 10, flow rate 1.00 mL/min, λ = 220 
nm, rt): tR (major) = 26.6 min, tR (minor) = 13.2 min. 









white solid, yield 95%; 1H NMR (500 MHz, CDCl3) δ 8.22 (d, J = 7.20 Hz, 
1H), 7.78 (d, J = 8.0 Hz, 1H), 7.33 (t, J = 7.9 Hz, 1H), 7.29-7.24 (m, 1H), 7.21 
(t, J = 7.9 Hz, 1H), 7.14-7.11 (m, 2H), 6.83 (d, J = 8.0 Hz, 1H), 6.30 (s, 1H), 
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3.74 (s, 3H), 1.60 (s, 9H), 1.32 (s, 9H), 1.19 (s, 9H). 13C NMR (125 MHz, 
CDCl3) δ 173.99, 159.45, 154.93, 153.12, 149.13, 138.79, 134.55, 129.22, 
128.89, 126.38, 124.47, 121.96, 115.40, 114.80, 114.59, 84.25, 83.09, 80.96, 
72.53, 60.41, 55.22, 28.12, 28.05, 27.74.. HRMS (m/z): [M+H]+ calcd for 
C30H39N3O8+ 570.281, found 570.2809. Enantiomeric excess: 97.4%, 
determined by HPLC (Chiralpak AD-H, hexane/i-PrOH = 97:3, flow rate 1.00 
mL/min, λ = 220 nm, rt): tR (major) = 64.7 min, tR (minor) = 46.8 min. 











white solid, yield 76%; 1H NMR (500 MHz, CDCl3) δ 8.27 (d, J = 7.2 Hz, 
1H), 7.77  (d, J = 7.8 Hz, 1H), 7.47 (d, J = 8.2 Hz, 2H), 7.34-7.28 (m, 4H), 
6.27 (s, 3H), 1.60 (s, 9H), 1.27 (s, 9H), 1.26 (s, 9H), 1.17 (s, 9H). 13C NMR 
+ calcd for C33H45N3O7+ 596.333, found 596.3321. 
Enantiomeric excess: 96%, determined by HPLC (Chiralpak AD-H, hexane/i-
PrOH = 90: 10, flow rate 1.00 mL/min, λ = 220 nm, rt): tR (major) = 13.4 min, 
tR (minor) = 6.7 min. 
 
(125 MHz, CDCl3) δ 174.7, 155.1, 153.5, 152.3, 149.6, 139.1, 130.0, 129.9, 
129.1, 126.8, 125.6, 124.7, 115.1, 84.6, 83.4, 81.1, 72.7, 34.9, 31.6, 28.5, 28.4, 
28.1. HRMS (m/z): [M+H]
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colorless oil, yield 87%; 1H NMR (500 MHz, CDCl3) δ. 8.24 (d, J = 7.3 Hz, 
, 131.97, 131.91, 129.34, 129.16, 126.51, 124.72, 
 (m/z): [M+H]+ calcd for C29H36FN3O7+ 558.271, found 558.271. 
Enantiomeric excess: 96%, determined by HPLC (Chiralpak AD-H, hexane/i-
PrOH = 90: 10, flow rate 1.00 mL/min, λ = 220 nm, rt): tR (major) = 32.4 min, 
tR (minor) = 13.0 min. 
Compound 63g: Di-tert-butyl 1-(1-(tert-butoxycarbonyl)-5-methoxy-2-
oxo-3-(p-tolyl)indolin-3-yl)hydrazine-1,2-dicarboxylate.  
1H), 7.80 (d, J = 8.0 Hz, 1H),  7.57 – 7.50 (m, 2H), 7.39 – 7.33 (m, 1H), 7.32 
– 7.28 (m, 1H), 7.02 – 6.96 (m, 2H), 6.30 (s, 1H), 1.61 (s, 9H), 1.32 (s, 9H), 
1.19 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 174.24, 164.02, 162.04, 155.02, 
153.13, 149.19, 138.91









hite solid, yield 94%; 1H NMR (500 MHz, CDCl3) δ 7.90 (d, J = 2.0 Hz, 
1H), 7.70  (d, J = 8.8 Hz, 1H), 7.40 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 8.3 Hz, 
w
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2H), 6.86 (dd, J = 8.9 and 2.7 Hz, 1H), 6.26 (s, 1H), 3.87 (s, 3H9, 2.29 (s, 3H), 
1.58 (s, 9H), 1.29 (s, 9H), 1.21 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 174.25, 
156.92, 154.84, 153.32, 149.35, 138.87, 132.29, 130.81, 130.25, 129.63, 
129.11, 115.81, 114.03, 112.61, 84.07, 83.17, 80.94, 72.73, 55.89, 28.24, 
28.13, 27.88, 21.15. HRMS (m/z): [M+H]+ calcd for C31H41N3O8+ 584.2966, 
found 584.2969. Enantiomeric excess: 98%, determined by HPLC (Chiralpak 
OD-H, hexane/i-PrOH = 99: 1, flow rate 1.00 mL/min, λ = 220 nm, rt): tR 
(major) = 11.9 min, t  (minor) = 8.7 min. R









 white solid, yield 92%; 1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 2.4 Hz, 
1H), 7.70  (d, J = 8.8 Hz, 1H), 7.23-7.19 (m, 1H), 7.12 (bs, 2H), 6.87 (dd, J = 
8.9 and 2.7 Hz, 1H), 6.84 (d, J = 7.95 Hz, 1H), 6.28 (s, 1H), 3.87 (s, 3H), 3.75 
3O9+ 600.2915, found 600.2909. 
Enantiomeric excess: 97%, determined by HPLC (Chiralpak OD-H, hexane/i-
rOH = 99:1, flow rate 1.00 mL/min, λ = 220 nm, rt): tR (major) = 18.1 min, tR 
inor) = 10.7 min. 
(s, 3H), 1.59 (s, 9H), 1.31 (s, 9H), 1.22 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 
174.3, 159.8, 157.2, 155.2, 153.6, 149.5, 135.2, 132.6, 130.9, 129.6, 122.2, 
116.1, 115.6, 114.9, 114.6, 112.7, 84.4, 83.5, 81.3, 73.2, 56.2, 55.6, 28.5, 28.4, 
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 colorless oil, yield 91%; 1H NMR (500 MHz, CDCl3) δ. 7.92 (d, J = 2.2 Hz, 
1H), 7.73  (d, J = 8.9 Hz, 1H), 7.57 – 7.51 (m, 2H), 7.03 – 6.98 (m, 2H),  6.89 
(dd, J = 8.9, 2.7 Hz, 1H), 6.29 (s, 1H), 3.88 (s, 3H), 1.60 (s, 9H), 1.31 (s, 9H), 
131.22 (s, 9H).  C NMR (100 MHz, CDCl3) δ 174.11, 171.19, 163.93, 162.02, 
pak AD-H, hexane/i-





157.05, 154.88, 153.19, 149.24, 132.31, 131.85, 131.78, 115.96, 115.33, 
115.16, 114.22, 112.66, 84.32, 83.37, 81.20, 72.23, 55.90, 28.22, 28.10, 27.87. 
HRMS (m/z): [M+H]+ calcd for C30H38FN3O8+ 588.2716, found 588.2711. 
Enantiomeric excess: 73%, determined by HPLC (Chiral
R
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colorless oil, yield 93%; 1H NMR (500 MHz, CDCl3) δ 8.26 (s, 1H), 7.85 (d, J 
= 8.9 Hz, 1H), 7.26 – 7.20 (m, 2H), 7.11 (d, J = 7.5 Hz, 1H), 7.04 (s, 1H), 6.87 
(dd, J = 8.2, 2.5 Hz, 1H), 6.28 (s, 1H), 3.73 (s, 1H), 1.60 (s, 9H), 1.32 (s, 9H), 
1.23 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 173.54, 159.76, 154.98, 153.21, 
149.12, 146.04, 137.52, 133.92, 129.62, 121.86, 121.83, 120.05, 116.06, 
115.51, 114.96, 84.91, 83.59, 81.38, 72.57, 55.34, 28.28, 28.19, 27.93. HRMS 
(m/z): [M+H]+ calcd for C30H38F3N3O9+ 654.2633, found 654.2633 . 
Compound 63k: Di-tert-butyl 1-(1-(tert-butoxycarbonyl)-5-fluoro-3-(3-
Enantiomeric excess: 93%, determined by HPLC (Chiralpak AD-H, hexane/i-
PrOH = 98: 2, flow rate 1.00 mL/min, λ = 220 nm, rt): tR (major) = 50.7 min, 









 colorless oil, yield 87%; 1H NMR (500 MHz, CDCl3) δ 8.07 (d, J = 5.8 Hz, 
1H), 7.78  (dd, J = 8.9, 4.5 Hz, 1H), 7.25-7.21 (m, 1H), 7.12-7.08 (m, 2H), 
7.06-7.02 (m, 1H), 6.86 (dd, J = 8.2, 2.4 Hz, 1H), 3.76 (s, 3H), 1.60 (s, 9H), 
13 .98, 
159.64, 159.05, 154.98, 153.13, 149.16, 134.90, 134.11, 129.45, 121.96, 
116.20, 115.42, 114.78, 114.25, 114.04, 84.57, 83.49, 81.29, 77.41, 77.16, 
76.91, 72.58, 55.40, 28.22, 28.13, 27.90. HRMS (m/z): [M+H]+ calcd for 
C30H38FN3O8+ 588.2716, found 588.2707 . Enantiome
determined by HPLC (Chiralpak OD-H, hexane/i-PrOH = 99: 1, flow rate 1.00 
1.32 (s, 9H), 1.24 (s, 9H) . C NMR (100 MHz, CDCl3) δ 173.68, 160
ric excess: 87%, 
mL/min, λ = 220 nm, rt): tR (major) = 10.2 min, tR (minor) = 7.4 min. 
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J = 6.3, 1H), 1.92 (t, J = 10.9, 1H), 1.66 (br, 1H), 
, 1H). 13C NMR (125 MHz, CDCl3): δ 156.45, 
147.92, 147.77, 144.10, 140.52, 137.30, 131.59, 128.88, 126.56, 126.43, 
126.06, 121.79, 118.56, 114.53, 103.05, 71.42, 69.90, 59.58, 49.77, 49.36, 
39.85, 28.05, 26.17, 21.37.  HRMS: calcd for C46H50N4O4 (MH+) 723.3905, 
found 723.3901. 
1H NMR (500 MHz, CDCl3): δ 8.61 (d, J = 4.5, 1H), 7.96 (d, J = 9.2, 1H), 
7.50 (s, 1H), 7.48 (d, J = 4.5,  1H), 7.38  (dd, J = 9.2, 2.6, 1H), 7.31 (s, 2H), 
7.48 (d, J = 2.5,  1H), 6.02-5.95 (m, 1H), 5.45 (d, J = 3.9, 1H), 5.27 (d, J = 
13.0, 1H), 5.15 (d, J = 13.0, 1H). 5.02 (br, 1H), 4.99 (d, J = 4.3,  1H)
3.20 (m, 1H), 2.91-2.87 (m, 1H), 2.67-2.62 (m, 1H), 2.53 (t, J = 10.6, 1H), 
2.39-2.35 (m, 1H), 2.11 (q, 
1.38-1.33 (m, 2H), 1.07-1.02 (m








N XI  
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white solid, 1H NMR (500 MHz, CDCl3) δ 8.73 (dd, J = 4.3, 1.6 Hz, 1
(d, J = 4.5 Hz, 1H), 8.02
H), 8.54  
 – 7.94 (m, 2H), 7.76 (d, J = 9.2 Hz, 1H), 7.60 – 7.58 
(m, 2H), 7.47 – 7.40 (m, 4H), 7.31 – 7.27 (m, 2H), 7.15 – 7.12 (m, 2H), 6.98 
(d, J = 2.4 Hz, 1H), 6.42 (s, 1H), 6.02 (ddd, J = 17.5, 10.0, 7.5 Hz, 1H), 5.24 – 
5.13 (m, 4H), 5.08 (d, J = 13.3 Hz, 1H), 4.90 (d, J = 13.3 Hz, 1H), 4.30 – 4.25 
(m, 1H), 3.26 – 3.20 (m, 1H), 3.10 – 3.05 (m, 1H), 3.03 – 2.82 (m, 2H), 2.47 – 
2.41 (m, 1H), 2.33 – 2.25 (m, 1H), 1.76 – 1.64 (m, 1H), 1.47 – 1.38 (m, 1H), 
2, 121.81, 118.97, 
117.76, 107.03, 101.20, 70.67, 70.12, 60.82, 60.42, 49.66, 48.98, 38.29, 28.01, 
1; HRMS (m/z): [M+H]+ calcd for C36H35N3O3+ 
0.91 – 0.82 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 157.15, 148.44, 147.68, 
144.80, 144.26, 138.00, 137.28, 136.98, 135.35, 131.93, 131.27, 129.67, 
129.11, 127.21, 126.96, 126.57, 125.72, 123.09, 122.8
24.10, 21.46, 18.49, 14.6
558.275 found 558.276. 
Compound XII: (S)-(6-(3-(phenoxymethyl)benzyloxy)quinolin-4-








 yellow solid, 1H NMR (500 MHz, CDCl3) δ 8.53 (d, J = 4.5 Hz, 1H), 7.98 (s, 
1H), 7.74 (d, J = 9.2 Hz, 1H), 7.59 (d, J = 4.4 Hz, 1H), 7.54 (s, 1H), 7.47 – 
m, 1H), 1.92 – 1.82 (m, 1H), 1.78 – 1.66 (m, 
1H), 1.55 – 1.41 (m, 1H), 0.95 – 0.81 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 
7.41 (m, 1H), 7.39 – 7.33 (m, 2H), 7.31 – 7.22 (m, 2H), 7.11 (dd, J = 9.2, 2.3 
Hz, 1H), 7.02 – 6.89 (m, 4H), 6.44 (s, 1H), 6.04 (ddd, J = 17.5, 10.0, 7.5 Hz, 
1H), 5.25 – 5.16 (m, 2H), 5.15 – 5.03 (m, 3H), 4.90 (d, J = 13.2 Hz, 1H), 4.35 
– 4.23 (m, 1H), 3.33 – 3.19 (m, 1H), 3.15 – 3.05 (m, 1H), 3.03 – 2.89 (m,1H), 
2.53 – 2.41 (m, 1H), 2.37 – 2.27 (
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161.83, 158.00, 155.97, 146.42, 144.00, 142.97, 136.69, 136.34, 136.14, 
130.63, 128.71, 127.79, 125.86, 125.76, 125.37, 121.66, 120.15, 117.80, 
116.57, 114.11, 100.05, 69.13, 69.02, 66.19, 59.26, 48.48, 47.79, 37.08, 35.71, 
30.66, 26.86, 22.88, 17.25;  HRMS (m/z): [M+H]+ calcd for C33H34N2O3+ 
507.2642 found 507.2638 
 3l)4 
aper and washed with 
MeOH. The filtrate was concentrated under reduced pressure to give a pale 
3l (25.5 mg, 0.11 mmol, 
63% yield) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.93 (brs, 1H), 
7.49 – 7.44 (m, 2H), 7.36 – 7.30 (m, 2H), 7.29 – 7.27 (m, 1H), 7.26 – 7.24 (m, 
2H),  7.07 – 7.02 (m, 1H), 6.94 (d, J = 7.4 Hz, 1H), 2.16 (brs, 2H). 13C NMR 
(100 MHz, CDCl3) δ 182.16, 141.10, 140.44, 129.55, 129.04, 128.31, 126.06, 
III. Synthetic route to 3-amino aryl oxindoles (compound
 
Compound 3l:  To a 4 M HCl solution in 1,4-dioxane (1.5 mL) at room 
temperature was added compound 3a (100 mg, 0.18 mmol). The reaction 
mixture was stirred for 2 h at room temperature. The reaction mixture was 
evaporated to give the crude material, which was used for the next step 
without purification. To a round bottom flask with this crude material was 
added MeOH (1.5 mL) and Rh/C (50 mg). The reaction was stirred for 12 h at 
rt under H2 (1 atm), then was filtered through a filter p
yellow solid. The residue was purified by silica gel flash column 
chromatography (30% DCM in AcOEt) to afford 
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125.54, 123.72, 110.55, 64.66. HRMS (m/z): [M+H]+ calcd for C14H12N2ONa+ 
247.0842, found 247.0841. Enantiomeric excess: 98%, determined by HPLC 
(Chiralpak AD-H, hexane/i-PrOH = 90: 10, flow rate 1.00 mL/min, λ = 220 
nm, rt): tR (major) = 18.2 min, tR (minor) = 25.6 min. 
 





.59 (s, 9H), 1.09 (t, J = 7.0 Hz, 3H), 1.04 (t, J = 7.0 Hz, 3H). C 
NMR (125 MHz, CDCl3) δ 174.08, 156.2, 154.8, 149.4, 139.5, 132.9, 130.1, 
129.6, 129.5, 128.8, 128.6, 128.5, 126.9, 124.8, 115.3, 84.7, 73.0, 63.5, 62.4, 
 
Compound 3m:  Diethyldiazocarboxylate (15 µL, 0.096 mmol, 1.2 equiv) 
was added to a solution of oxindole 61a (25 mg, 0.08 mmol, 1 equiv.) and 
catalyst IX (2.9 mg, 0.05 equiv.) in toluene (0.8 mL) at -70 C. The resulting 
solution was stirred at -70 0C for 24 h. The reaction mixture was then 
quenched with a saturated aqueous ammonium chloride solution. The aqueous 
layer was separated and extracted with ethylacetate (3x). The combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The crude material was purified by flash column chromatography 
(hexanes/ethyl acetate; 4:1) to afford compound 63m in 88% yield; 1H NMR 
(500 MHz, CDCl3) δ 8.16 (d, J = 7.4 Hz, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.54 
(bs, 2H), 7.36 (t, J = 7.8 Hz, 1H), 7.34-7.30 (m, 4H), 6.63 (s, 1H), 4.04-3.99 
(m, 4H), 1 13
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L/min, λ = 220 nm, rt): tR 
(major) = 29.2 min, tR (minor) = 14.2 min.  
Compound 63n:  Dichloromethane (75 µL) and TFA (75 µL) were added to 
the flask containing compound 63m (30 mg, 0.062 mmol). The resulting 
mixture was stirring for 1 h at room temperature. The reaction mixture was 
then quenched with a saturated aqueous NaHCO he aqueous layer 




28.5, 14.7, 14.3. Enantiomeric excess: 80%, determined by HPLC (Chiralpak 
AD-H, hexane/i-PrOH = 90: 10, flow rate 1.00 m
3 solution. T
was separated and extracted with dichloromethane (3x). The combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
material was purified by flash column chromatography (hexanes/ethyl acetate; 
1:1) to afford compound 63n in 84% yield (20 mg). H NMR (500 MHz, 
CDCl3) δ8.06 (d, J = 7.4 Hz, 1H), 7.63-7.61 (m, 2H), 7.30 (s, 4H), 7.14 (t, J = 
7.4 Hz, 1H), 6.82 (d, J = 7.7 Hz, 1H), 6.67 (bs, 1H), 4.06-4.00 (m
(bs, 1H), 1.10 (t, J = 7.0 Hz, 3H), 1.05-1.04 (m, 3H); HRMS (m/z): [M+H]+ 
calcd for C20H21N3O5+ 384.2078, found 384.1558. [α]D20 = -101.3 (c = 0.92; 
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